Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices

  • Sep 19, 2012

Quick Summary

A PDMP is a statewide electronic database that gathers information from pharmacies on dispensed prescriptions for controlled substances. This white paper describes what is known about PDMP best practices and documents the extent to which these practices have been implemented.
Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices
Full Report PDF Download Chart Icon

Report Topic

PDMP Practices and Evidence for Best Practices

IV. PDMP Practices and Evidence for Best Practices

In this section, we survey candidate PDMP best practices, the evidence for their effectiveness, the extent to which they are currently adopted by states, and barriers to their adoption. It is organized by PDMP workflow, starting with data collection, followed by data linking and analysis, user access and reporting, recruitment, utilization, and user education. The last three headings in this section consider candidate best practices to facilitate collaboration among PDMPs and agencies concerned with prescription drug abuse; best practices with respect to PDMP evaluation; and options for the sustainable funding of PDMPs. After each practice is a thumbnail summary of its rationale, evidence base, current adoption status, and barriers to adoption. 

In some cases, practices adopted by some states or thought potentially effective have no current evidence in the first category mentioned above (published studies, data analyses, or consensus statements). However, these practices are included for consideration since their possible effectiveness is suggested by evidence in the second category (accumulated experience in their application and/or perceptions of key stakeholders). Note that all the practices considered below have at least some support from the second category of evidence; this will be described in the text. However, the thumbnail summary of evidence for a practice will mention such support only when evidence from the
first category is absent. 

Data collection and data quality

Best practices in data collection, quality, and timeliness will permit more complete, accurate, and up-to-date data analyses and reports to end users. Candidate practices include actions to:

A. Standardize data fields and formats across PDMPs

  1. Collect data on all schedules of controlled substances
  2. Adopt uniform and latest ASAP reporting standard 
  3. Collect data on nonscheduled drugs implicated in abuse 
  4. Collect positive identification for the person picking up prescriptions 
  5. Collect data on method of payment, including cash transactions
B. Reduce data collection interval; move toward real-­time data collection
C. Institute serialized prescription forms
D. Integrate electronic prescribing with PDMP data collection
E. Improve data quality: pharmacy compliance, error, and missing data correction

A.  Standardize data fields and formats across PDMPs

Currently, PDMPs vary in the data fields and formats collected from pharmacies, limiting the comprehensiveness of data, comparability of data across states, and ease of integration with prescription information collected by potential PDMP collaborators, such as Medicaid, the Indian Health Service (IHS), Department of Veterans Affairs (VA), and Department of Defense (DoD).

1. Collect  data  on  all  schedules  of  controlled  substances    

Rationale: A possible best practice in data collection, widely adopted but not universal among PDMPs, is to collect prescription history information on all classes of controlled substances (Schedules II-V). This practice is included in the Alliance of States with Prescription Monitoring Programs’ PMP Model Act (ASPMP, 2010) and will permit prescribers and pharmacists to examine the full spectrum of controlled substance prescriptions when making clinical decisions about patients. Although opioids are perhaps the most widely abused and diverted drugs, drugs in all schedules have abuse potential. For example, by 2009, there were almost as many emergency department visits associated with misuse or abuse of benzodiazepines (373,200) as for opioids (393,200) (SAMHSA, 2010), and persons who are seriously abusing drugs frequently abuse multiple controlled substances (SAMHSA, 2011). Moreover, suspected questionable activity (e.g., doctor shopping) is associated with being prescribed multiple classes of drugs. PDMPs not tracking all classes will likely underestimate the prevalence of doctor shopping (Wilsey et al., 2010) and thereby fail to inform all affected providers about problematic prescribing and dispensing. BJA has designated collecting data on all schedules a priority for PDMPs seeking funding under its Harold Rogers Grant Program.

Evidence of effectiveness: A preliminary evaluation of Performance Measure Reports submitted by Harold Rogers grantee PDMPs to BJA suggests that states collecting Schedules II-V have lower rates of doctor shopping than states collecting fewer schedules (PDMP COE analysis of Performance Measure Data, 2011).

Current adoption status: According to the Alliance of States with Prescription Monitoring Programs, of 46 states that have established reporting requirements, only 29 require reporting of Schedules II-V; see­‐profiles-­‐reports.

Barriers to adoption: Tracking all drug schedules involves updating data collection systems and the need for regulation and/or legislation changes.


Rationale: Prescribers need to examine all scheduled drug classes to make proper prescribing decisions; all classes are subject to abuse; collecting all schedules permits improved detection of questionable activity.

Evidence of effectiveness: Unpublished PDMP COE data analysis, expert opinion (ASPMP Model Act).

Current adoption status: 46 states have established reporting requirements; 29 require reporting of Schedules II-­V.

Barriers to adoption: Costs of updating systems, requires legislative and/or regulatory change.

2. Adopt  uniform  and  latest  ASAP  reporting  standard  

Rationale and evidence of effectiveness: Having uniform and modernized data collection standards common to all PDMPs would have many advantages, including the facilitation of cross-­state data sharing, multistate data analyses, public health analyses, and collaborations with other organizations collecting and making use of prescription history data, such as the Indian Health Service, Department of Defense, VA, Medicaid, and Medicare. The Alliance of States with
Prescription Monitoring Programs PMP Model Act 2010 Revision recommends that all PDMPs collect a minimum common set of data fields (ASPMP, 2010). Continuously updated standards for pharmacy data fields and formats, including those reported to PDMPs, are set by the ASAP. The more recent standards make more data fields available,
simplify data correction, and permit additional data reporting functionalities, such as tracking method of payment (see 5.  Collect  data  on  method   of  payment, below) (PDMP COE, NFF 3.1). Updating to more recent ASAP standards may therefore improve the performance and effectiveness of individual PDMPs. A potential best practice is for all PDMPs to move to the latest standard, 4.2, released in 2011, and then move in concert to new versions as they are released. Under its Harold Rogers Grant Program, BJA gives priority consideration to PDMPs proposing to adopt the latest ASAP standard.

Current adoption status: All PDMPs use ASAP standards, but adoption of the most current version by many PDMPs has usually taken years. For example, in February 2012, of 40 operational PDMPs, 5 were using the 2005 version 3.0, 5 were using the 2007 version 4.0, 13 were using the 2010 version 4.1 (data compiled by PDMP COE), and the 17 remaining PDMPs were using older versions.

Barriers to adoption: Barriers to adoption include the need to change some states’ laws and/or regulations that identify a specific ASAP version, and the costs and staff time necessary to implement ASAP upgrades for state PDMPs and for pharmacy software systems. Given their cumulative experience in making system improvements, many PDMPs and pharmacies are becoming increasingly efficient in adopting new standards, so the cost of future upgrades will likely decrease.


Rationale: Uniform data standard may facilitate cross-­‐state data sharing, analyses, and inter-organizational collaboration; more recent standards provide more complete data fields, improve error correction, and provide additional reporting functionalities.

Evidence of effectiveness: Case study, expert opinion.

Current adoption status: Of 40 operational PDMPs (as of February 2012), 5 were using ASAP version 3.0,
5 were using version 4.0, 13 were using version 4.1, and the 17 remaining PDMPs were using older versions.

Barriers to adoption: Upgrade costs, staff resources. 

3. Collect  data  on  nonscheduled  drugs  implicated  in  abuse

Rationale and evidence of effectiveness: Certain drugs not federally scheduled or scheduled by most states, such as tramadol and certain formulations of butalbital, are sometimes abused, as when mixed in “drug cocktails” with opiates and benzodiazepines. The Alliance of States with Prescription Monitoring Programs’ PMP Model Act 2010 Revision suggests that states may wish to track noncontrolled substances that are judged to demonstrate “a potential for abuse” (ASPMP 2010). Some drugs used to manufacture methamphetamine, such as ephedrine and pseudoephedrine, are also unscheduled in most states. PDMPs that track these drugs will likely be better positioned to detect pill mills that specialize in drug cocktail combinations and possible hot spots of methamphetamine production. A comprehensive list of unscheduled substances that merit tracking by PDMPs could be developed. Systematic investigation of the outcomes of such tracking is needed to evaluate it as a possible best practice. No formal studies have yet been conducted.

Current adoption status: Nearly a third of states with active PDMPs are tracking some of these drugs (ASPMP state profiles).

Barriers to adoption: The costs of adding these drugs to PDMP data collection would likely be minimal in most cases, but objections to adding them include concerns about compromising patient privacy, adding to regulatory burdens, and restricting access to substances that are not normally subject to scheduling controls or PDMP reporting. In many states, legislation and/or regulation changes would be required to give the PDMP authority to collect this information.


Rationale: Some nonscheduled drugs are implicated in abuse and illicit drug manufacture.

Evidence of effectiveness: Expert opinion.

Current adoption status: Approximately one-­third of PDMPs.

Barriers to adoption: Concerns about patient privacy, regulatory burdens, unnecessary restriction of access to nonscheduled medications, opposition by pharmaceutical manufacturers.

4. Collect  positive  identification  for  the  person  picking  up  prescriptions    

Rationale and evidence of effectiveness: Prescriptions are often dispensed to (picked up by) persons other than the individual for whom they are prescribed, creating an opportunity for diversion. As noted by the Massachusetts PDMP, "…in 38 percent of cases, the person dropping off or picking up the prescription is not the patient and, therefore, without the customer ID, there would be no record of who dropped off the prescription or picked up the controlled substance"
(Massachusetts Department of Public Health [MADPH], request to Public Health Council, 2010).  If the identification of the person picking up the prescription is not collected, prescribers and pharmacists are less able to make appropriate clinical decisions because they do not know if patients listed on PDMP prescription history reports actually received the medications. Likewise, the PDMP and other data users are unable to determine whether the patient or someone else had possession of the controlled substances. Unless identification is obtained by the pharmacy, the pharmacies and PDMPs are missing data that would help track possible diversion. These considerations suggest that collecting customer ID would help assure the proper use of controlled substances and deter prescription fraud, while simultaneously providing information that could be used to detect fraud, especially for cash transactions (see 5.  Collect  data  on  method  of  payment, below). Research is needed to confirm these hypotheses. How states actually use customer identification information, and the benefits accruing from such use, needs to be studied in order to further understand the value of collecting customer ID.

Current adoption status: Some states, including Connecticut, Delaware, Hawaii, Massachusetts, Michigan, Oklahoma, South Carolina, and Texas, require that the person picking up a prescription show positive identification and that the pharmacy record this information and report it to the PDMP (PDMP COE, Positive customer identification, 2010).

Barriers to adoption: Barriers to adopting positive ID requirements include the need to amend state laws and/or regulations, pharmacy concerns about increasing workload and lengthening transaction times, and patient rights groups’ worries that individuals lacking standard state IDs might be denied legitimate prescriptions. Nevertheless, experience in Massachusetts, which recently adopted a positive ID requirement, suggests that these barriers can be overcome by involving pharmacies and patient rights groups in drafting regulations. Examining other states’ adoption processes could
help to identify model practices in how to institute positive ID requirements.


Rationale: Collecting positive ID may permit better tracking of controlled substances upon dispensing.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: A few states collect positive customer ID.

Barriers to adoption: Legislation and regulation changes, increases in pharmacy workload, concerns regarding potential denial of legitimate prescriptions to those without identification.

5. Collect  data  on  method  of  payment,  including  cash  transactions  

Rationale and evidence of effectiveness: Collecting data on method of payment would add value to PDMP reports to end users. Method of payment, in particular cash transactions, can be an indicator of questionable activity such as doctor shopping. PDMP administrators and law enforcement investigators often cite cash payments as suggestive of doctor shopping, especially when the individual has health insurance. Pill mills usually accept only cash payments (Rigg et al., 2010). Paying with cash instead of by credit, health plan, or Medicaid/Medicare reduces the information available to identify the individual and helps to evade monitoring of prescription purchases by third-­‐party payers. For example, cash payments enable Medicaid enrollees to avoid detection by Medicaid Drug Utilization Review systems and to avoid Medicaid patient "lock-­‐in" programs in which patients are limited to a single prescriber and pharmacy. Provided with PDMP sources of payment information, state Medicaid programs could better detect doctor shoppers, place them in
lock-­in programs and monitor their compliance. According to the Coalition Against Insurance Fraud report Prescription for Peril (Coalition Against Insurance Fraud, 2007), persons who abuse prescription opioids incur excess health care costs totaling more than $72 billion annually to all public and private health insurers, including Medicaid. Recording the method of payment by all PDMPs and transmitting this information to Medicaid and third-­party payers would help reduce these costs. Examining the experience of PDMPs that require the reporting of method of payment, including how they use this information in analyses and reports and how they address privacy concerns, would help support such reporting as a best practice. 

Current adoption status: States that require reporting method of payment include Alaska, Arizona, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts, Michigan, Nevada, New York, North Dakota, and Oklahoma. Increasingly, states are providing data to Medicaid agencies. Six PDMPs were permitted to provide data to state Medicaid agencies in 2006; by 2010, the number had increased to 15 PDMPs (PDMP COE survey of PDMPs, 2010). In 2012, the State of Washington allowed the state workers’ compensation program to examine PDMP data. 

Barriers to adoption: Barriers to this practice include the fact that some PDMPs do not record method of payment due to use of an older ASAP standard that does not permit transmission of this data element. Concerns also exist about compromising patient privacy. 


Rationale: Information on method of payment may help detect doctor shopping and pill mills, may contribute to safe and effective prescribing by identifying patients at high risk.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: Several states collect method of payment.

Barriers to adoption: Using older ASAP data collection standards, concerns about patient privacy.

B.  Reduce data collection interval; move toward real-­‐time data collection

Rationale and evidence of effectiveness: State PDMPs receive updated prescription dispensing data from pharmacies at varying intervals, ranging from monthly to daily, with most pharmacies reporting every one or two weeks (ASPMP state profiles, 2011). This means that even PDMPs that supply end users with immediately available online reports are delivering data that often do not include patients’ most recent prescription purchases. These omissions compromise the utility of prescription history data for clinical practice and drug diversion investigations (PDMP COE, NFF 2.3). 

The Alliance of States with Prescription Monitoring Programs’ PMP Model Act 2010 Revision recommends that pharmacies submit prescription data “no more than seven days from the date each prescription was dispensed” (ASPMP, 2010). Ideally, PDMP data would be collected in real time, within a few minutes of a drug being dispensed. PDMPs across the country report increased demands from prescribers, particularly emergency department physicians, for prescription histories of their patients that are complete at the time of seeing a patient. The Oklahoma PDMP has implemented real-‐time data collection, slated to be fully functional by the end of 2012; this will serve as a pilot test of the feasibility and benefits of such a system (PDMP COE, NFF 3.1). Data will be collected on the impact of the Oklahoma initiative on PDMP data quality, utilization by providers, and other outcomes, including overdoses from prescription drugs. Meanwhile, states can take incremental steps to reduce their data collection intervals from monthly to biweekly, weekly, or daily. States might also look to the Oklahoma experience as a guide to best practices in moving to real-­time data collection.

Current adoption status: States vary in their data collection interval, with most collecting every one or two weeks. While only the Oklahoma PDMP has implemented real-­time data collection and reporting, 2012 legislation enacted in New York State mandates pharmacies to submit data in real time to its PDMP; this provision goes into effect in 2013.

Barriers to adoption: The technical and logistical obstacles to real-­time data collection and reporting are significant but can be overcome, as demonstrated recently by the Oklahoma PDMP (see PDMP  COE,  NFF 3.1). Real-­‐time reporting will be difficult for many states to adopt soon given their limited resources.


Rationale: More timely data are expected to enable more informed prescribing and improved detection of questionable activity.

Evidence of effectiveness: Expert opinion.

Current adoption status:  States vary in data collection interval, most at one or two weeks; one state has implemented real-­time data collection.

Barriers to adoption: Cost, staff time, information technology hurdles. 

C.  Institute serialized prescription forms

Rationale and evidence of effectiveness: Prescription fraud and doctor shopping using counterfeit, copied, or stolen prescription forms is a common source of diverted and abused controlled substances. New York and Texas mandate the use of state-­printed serialized prescription forms (in Texas for Schedule II drugs only), each of which has a unique consecutive number; batches of forms are issued to each prescriber. The serial numbers of any stolen forms showing up in the PDMP database are flagged for investigation, as are any duplicated numbers. Experience in Texas (communication from former PDMP administrator) and New York (Eadie, 1990; Eadie, 1993) suggests that serialized forms help to reduce prescription fraud. Research indicates that three PDMP states using serialized forms (California, New York, and Texas) had lower increases in death rates from opioid overdose from 1999-­‐2005 (Paulozzi et al., 2011). Some states require use of so-­called tamperproof, but unserialized, prescription forms, but analysis of PDMP data from California suggests that these are not as effective in countering diversion as serialized forms (Gilson, 2011).

Current adoption status: Only New York and Texas use state-­printed serialized prescription forms (in Texas for Schedule II drugs only).

Barriers to adoption: Barriers to the adoption of serialized prescription forms include concerns that they might reduce access to legitimate prescriptions (the so-­called "chilling effect"), incur printing and distribution costs, and require record-­checking capabilities into the PDMP and pharmacy workflow. However, prescription data from Texas indicate that the forms have had no chilling effect (the number of Schedule II prescriptions issued has increased every year since the mid-­1980s); serialized forms in Texas are sold at cost to doctors and made readily available; and the forms’ serial numbers are easily scanned into pharmacy databases, along with the prescriber’s registration number, minimizing the
workflow burden.


Rationale: Serialized prescription forms appear to reduce prescription fraud and may be superior to unserialized tamperproof forms.

Evidence of effectiveness: Published studies.

Current adoption status: Texas and New York State; formerly California.

Barriers to adoption: Concerns about jeopardizing legitimate prescribing (the chilling effect), incurring printing and distribution costs, implementing record-­‐checking systems.

D. Integrate electronic prescribing with PDMP data collection

Rationale and evidence of effectiveness: As states implement systems of electronic prescribing of controlled substances (EPCS), the opportunity exists to integrate electronic medical records and EPCS systems with PDMP data. PDMPs could expand their data collection fields to include data specific to EPCS issued by prescribers and thereby facilitate communication with providers using an electronic prescribing (e-­prescribing) system. This would permit monitoring of prescriptions as they are being issued, prior to dispensing, and after dispensing. Matching the electronic prescription to the dispensing record would assure that the drug and dose dispensed were what was prescribed, enabling prescribers to better monitor patients’ compliance with their prescription drug treatment. This issue is timely as electronic prescribing of controlled substances is now expanding. For example, in 2012 legislation, New York State mandated that by the end of 2014 all prescriptions, including controlled substances, must be prescribed electronically with but with few exceptions (the "I-Stop" Program Bill #39, introduced in June 2012).

PDMPs could be made interoperable with e-­prescribing systems so that: 1) obtaining an e-prescribing certification for controlled substances would be accepted by PDMPs as authentication for access to PDMP data; 2) as prescribers enter the name of a controlled substance drug for e-prescription, the patient’s controlled substances history from the PDMP would appear on their electronic device; 3) as each e-­prescription is sent to a pharmacy, a copy would be routed to the PDMP database; and 4) as each e-prescription is dispensed, the PDMP would match the pharmacy's dispensing record to the corresponding e-­‐prescription from the prescriber to identify any alterations and, if any, report them to the appropriate agency.

Current adoption status: In 2012 legislation enacted in New York State, electronic prescribing of all controlled substances is mandated to begin in approximately three years, with limited exceptions. The method for integration with the state's PDMP is expected to be described in implementing regulations.

Barriers: Barriers to PDMP interoperability with e-­‐prescribing include lack of existing information technology protocols, policies, and standards to enable data exchange between systems.


Rationale: Integrating PDMPs with electronic prescribing may enable more reliable, complete, and timely prescription monitoring.

Evidence of effectiveness: Key stakeholder perceptions.

Current adoption status: None.

Barriers to adoption: Technological and regulatory hurdles.

E.  Improve data quality: pharmacy compliance, error, and missing data correction

Rationale: The quality of a PDMP’s output — analyses and reports, whether solicited or unsolicited — depends on the timeliness, completeness, accuracy, and consistency of collected data, or inputs. Best practices need to be identified for all stages of data collection and management, but little study of PDMP data quality processes has been conducted. Goals of good data management include:

  • attaining a high rate of reporting from all eligible pharmacies (high compliance rate);
  • accurate data entry by pharmacy personnel (low initial error rate);
  • correction of data when errors are identified (low final error rate after correction); and
  • identification and completion of missing data where possible (low missing data rate).

Since no agreed-­upon standards for PDMP data quality exist, quantitative benchmarks indicative of success for each of these goals need to be established. Policies and procedures that enable achieving the benchmarks need research and development.

Evidence of effectiveness: Recent experience with real-­time reporting of prescription information in Oklahoma (see B.  Reduce  data  collection  interval;  move  toward  real-­time  data collection, above) suggests that the advanced information systems required for real-­time reporting can play a significant role in improving error correction and detecting and completing missing data, as can moving to version 4.0 or more recent versions of the ASAP reporting standard (PDMP COE, NFF 3.1). For example, ASAP versions 4.1 and later enable pharmacy correction of data errors on a case-by-case basis. Prior versions require the PDMP to return a submitted batch of data found to have unacceptable errors to the pharmacy for correction and return of the whole batch, rendering that batch of data unavailable
for provider inquiry until the errors are corrected. It is also possible that other, less technically demanding updates in PDMP data management procedures and policies could produce improvements in data quality.

A survey of a sample of PDMPs comparing approaches to improving reporting compliance and data quality, and linking these to PDMP-­quantified performance measures such as data completeness and error rates, would help to identify promising practices. In evaluating a practice, the financial and practical feasibility of instituting the practice would be weighed against the data quality improvement it produced. For more on researching best practices in PDMP data quality, see Section V.  Summary  and  Recommendations, below.

Current adoption status: Data quality standards and policies, and procedures in support of achieving acceptable data quality, differ among PDMPs and likely produce varying degrees of success in their attainment.

Barriers to adoption: Barriers to data quality improvement include the cost in staff time of surveying current practices, lack of data quality standards, and lack of resources needed to update data quality systems.


Rationale: Complete and accurate data can improve reporting, are important for prescribers and pharmacists making patient care decisions, and can help in detecting questionable activity.

Evidence of effectiveness: Accumulated field experience, key stakeholder perceptions.

Current adoption status:  States vary in data quality practices.

Barriers to adoption: Cost of surveying current practices, lack of standards, resources needed to update data quality systems.

Data linking and analysis

Best practices in PDMP data linking and analysis will permit better identification of unique individuals in PDMP data, development of standard analyses comparable across states, more reliable estimates of questionable activity, more appropriate and applicable epidemiological investigations, expedited and more reliable analyses, and reports incorporating experienced user knowledge.

Candidate practices include actions to:

A. Link records to permit reliable identification of individuals

B. Determine valid criteria for possible questionable activity

C. Conduct periodic analyses of possible questionable activity

D. Conduct epidemiological analyses for use in surveillance, early warning, evaluation, and

E. Develop automated expert systems to expedite analyses and reports

F. Record data on prescriber disciplinary status and patient lock-­ins

A.  Link records to permit reliable identification of individuals

Rationale and evidence of effectiveness: Reliable identification of unique individuals in PDMP databases, whether patients or prescribers, is vital for accurate analyses and reporting of questionable activity and prescribing trends. Although states have implemented a number of approaches to link patient records, to date, there has been neither a census taken of such approaches, nor an evaluation of their effectiveness.

Standard benchmarks for reliable record linking need to be identified against which different linking algorithms can be tested. Since the capability to link records belonging to an individual is critical to providing accurate prescription information to all users and is essential for analyzing the impact of PDMPs, e.g., measuring the level of questionable activity, this is an area deserving of close examination for developing evidence-­‐based best practices. See Section  V.
Summary  and  Recommendations, below, for further discussion and recommendations.

Current adoption status: Many states have developed electronic capabilities to link prescriptions dispensed to what is likely to be a single individual in cases where the personal identifying information varies between records, e.g., the same address and prescriber but a differently spelled first name. Such linking is accomplished through vendor proprietary software, off-­the-shelf software, or in-house developed or modified software.

Barriers to adoption: Barriers to adopting reliable record linking systems include lack of standard benchmarks to assess linking algorithms and lack of resources to conduct research to develop standards.


Rationale: Reliable linking of records maximizes identification of unique individuals in PDMP data.

Evidence of effectiveness: Key stakeholder perceptions.

Current adoption status: States vary in whether and how records are linked.

Barriers to adoption: Lack of resources to conduct needed research, no standard benchmarks to assess linking algorithms.

B.  Determine valid criteria for possible questionable activity

Rationale and evidence for effectiveness: Despite the relatively widespread use of unsolicited reporting (see User  access  and  report  dissemination,  E.  Send  unsolicited  reports  and  alerts  to  appropriate  users, below) on individuals exhibiting possible questionable activity (e.g., doctor shopping), there is little commonality in the criteria used by PDMPs to identify them. Validated and standardized criteria are therefore needed to permit reliable identification of questionable activity within and across jurisdictions. Proactive reporting is also applicable to medical providers who, whether intentionally or not, may be engaging in risky or illegal prescribing or dispensing behavior. Alerts concerning questionable activity on the part of providers may be appropriately addressed to licensure boards,
peer review committees, third-­party payers, Centers for Medicare and Medicaid Services (CMS), and other bodies or agencies concerned or charged with monitoring medical practitioners. When analysis of PDMP data identifies probable criminal activity, such as prescribing by pill mills, referral to law enforcement agencies would be appropriate. To guide such alerts, reliable criteria of questionable activity by providers using PDMP and other data need research and development; see, for instance, DuBose et al. (2011).

Several studies have attempted to shed light on criteria for identifying conditions and behaviors that put patients at risk for prescription drug abuse. Patients who visit a few prescribers (two to five) in a year seem not to be more at risk for opioid abuse than those using only one (Wilsey et al., 2011). Studying a sample of insurance patients on whom they were able to obtain medical records, White et al. (2009), found that the risk for prescription opioid abuse (over a three-­month period) was associated with being age 18 to 34, being male, filling four or more opioid prescriptions, having opioid
prescriptions from two or more prescribers and from two or more pharmacies, using early prescription opioid refills, and obtaining escalating dosages. When medical data were allowed to be predictors in the model of risk for prescription opioid abuse, such risk (over a 12-month period) was found to be associated with being age 18 to 34, being male, filling 12 or more opioid prescriptions, having opioid prescriptions from three or more pharmacies, using early prescription opioid refills, and obtaining escalating dosages, in addition to having hospital and outpatient visits and several diagnoses.

In a sample of users of high-­dosage buprenorphine, Pauly et al. (2011) compared the patient groups identified by (1) overlapping prescriptions (early refills) and (2) outliers in a distribution of patients based on number of prescriptions, number of prescribers, and number of pharmacies. These researchers found that the two groups had an 85 percent overlap. Other studies have implicated simultaneous, or overlapping, prescriptions for different controlled substances (e.g., opioids and benzodiazepines) as being associated with multiple prescriber episodes (Wilsey et al., 2010) or
opioid-­related deaths (Webster et al., 2011; Rich & Webster, 2011).

Paulozzi et al. (2012) were able to link a sample of patients in New Mexico who died of an unintentional drug overdose with PDMP data to obtain their prescription histories. Comparing these histories to prescription histories of a control sample with matching exposure periods in the PDMP database, these researchers found that increased risk for overdose death was associated with being male; being older; filling a certain number of prescriptions; filling prescriptions for a
sedative/hypnotic, buprenorphine, and specific opioids; and receiving a daily average of 40 or more morphine milligram equivalents. A parallel study in Washington State found that patients receiving opioid prescriptions with an average daily
dosage of 100 or more morphine milligram equivalents were 8.9 times as likely to die of overdose as patients receiving an average daily dosage of 1 to 20 morphine milligram equivalents (Dunn et al., 2010). An association between doctor shopping, receiving a high daily dose, and risk of overdose death is also suggested by research conducted by Hall et al. (2008), Gomes et al. (2011) and Peirce et al. (2012).

These studies suggest the utility of including factors other than number of prescribers and number of pharmacies in a specified period of time as criteria for identifying questionable activity or likely doctor shopping behavior. Moreover, indicators of doctor shopping behavior may well vary across states and over time,² and it is important to distinguish between (1) criteria that most accurately identify individuals engaged in questionable activity, and (2) criteria that, if used as the basis for sending unsolicited reports, would generate the most benefit in terms of facilitating appropriate
prescribing and reducing abuse and diversion. To date, no studies have compared the effects of unsolicited reporting using different criteria within the same PDMP. Studies to refine the criteria for sending unsolicited reports would appear
useful to the extent they can reduce the number of false positives (possibly creating unnecessary patient discomfort) and false negatives, thereby increasing the efficiency of PDMP resources used to generate the reports.

² - For example, as shown in PDMP COE, Notes from the Field 1.1 and 2.5, as states issue unsolicited reports, the numbers of persons exceeding the thresholds can be expected to decline. Thus a state could lower its thresholds to identify possible doctor shoppers who are obtaining fewer prescriptions.

The purpose of an unsolicited report, however, is to provide prescribers and pharmacists with additional information that they may choose to use (or not) in their clinical decision-­making. This line of reasoning suggests that, for maximum effect, unsolicited reporting ought to be coupled with efforts to educate prescribers and pharmacists about how to access and use PDMP data.

Exploratory work being done by the Massachusetts and Nevada PDMPs to automate their reporting to health providers of persons who exceed thresholds should be followed closely, as automation may provide a means by which to increase reporting capabilities while decreasing costs. To avoid bottlenecks in proactive reporting, data quality and criteria for questionable activity need development to the point where unsolicited reports and alerts do not have to be reviewed by hand before they are sent (see Develop  automated  expert  systems, below).

Current adoption status: To identify possible doctor shoppers, PDMPs typically use a threshold of a number of prescribers from whom a patient has obtained a controlled substance prescription, and a number of pharmacies that have dispensed the prescriptions, in a specified period of time — often six months but sometimes one month. For example, BJA’s required performance measures for PDMP Harold Rogers grantees asks for the number of patients who have obtained, respectively, Schedule II, Schedule II and III, and Schedule II–IV prescriptions from five or more prescribers and had them filled at five or more pharmacies in a three-month period (a 5x5x3 threshold).³  Some PDMPs use thresholds as high as 10 prescribers and 10 pharmacies in a one-­month period (10x10x1).

Several factors appear to account for the different thresholds used across PDMPs. The earliest thresholds (e.g., Nevada's) appear to reflect the judgment of the state’s Prescription Controlled Substances Abuse Prevention Task Force that patients engaged in this level of activity are very likely doctor shopping. In other cases, the thresholds used reflect the PDMP’s limited resources to generate such reports: Thresholds are set high to identify the persons most significantly involved in doctor shopping and to minimize the number of unsolicited reports that would be called for.

In some cases, thresholds are augmented by the review of a PDMP administrator experienced in identifying likely cases of fraud, abuse, or diversion. Katz et al. (2010) point out that varying the threshold numbers of prescribers and pharmacies from whom a patient has obtained prescriptions enables a PDMP to trade off false positives (flagging via an unsolicited report of patients not engaged in questionable activities or doctor shopping) and false negatives (failing to flag patients actually engaged in questionable activities or doctor shopping). However, as noted above,
there are currently no recommended best-­practice criteria for identifying patients on whom unsolicited reports should be

Barriers to adoption: Barriers to determining valid criteria for possible questionable activity include lack of a coordinated research program to develop such criteria, the need for a systematic review of existing criteria and their effectiveness, and lack of agreed upon standards by which such effectiveness would be measured, for instance what constitutes an acceptable balance between false positives on the one hand and capturing the full spectrum of questionable activity on the other.

³ - Through June of 2010, these thresholds applied over a six-­‐month period. In July 2010, the period was changed to three months.

For further discussion and recommendations for research on establishing valid criteria for questionable activity, see Section  V.  Summary  and  Recommendations, below.


Rationale: Validated criteria for questionable activity are needed to target unsolicited reports and improve measures of doctor shopping and other questionable activity.

Evidence of effectiveness: Key stakeholder perceptions.

Current adoption status: Variation in thresholds and other criteria used by states.

Barriers to adoption: Lack of sufficient research to validate criteria.

C.  Conduct periodic analyses of possible questionable activity

Rationale: PDMP data are unique in providing estimates of possible doctor shopping and other questionable activity, either on the part of patients or prescribers. Such activity is a precursor to controlled substance diversion and abuse, and so is an indicator of a contributing cause of the prescription drug abuse epidemic. Since levels of questionable activity, such as the number of individuals meeting criteria for doctor shopping (see B.  Determine  valid  criteria  for  possible
 questionable  activity, above), are affected by the use of PDMPs, they can also serve as indicators of the impact of the PDMP and of program improvements, possibly providing evidence for PDMP effectiveness.

Current adoption status and evidence of effectiveness: The Virginia PDMP found that the number of individuals meeting thresholds for possible doctor shopping (10x10 and 15x15 in a six-­‐month period) declined following a large increase in data queries to the PDMP, in turn likely the result of improved access to PDMP data (Virginia Prescription Monitoring Program, 2010). Declines in numbers of individuals meeting doctor shopping thresholds subsequent to issuing unsolicited reports, as well as declines in prescribers, pharmacies, and dosage units for individuals reported on, have been observed in Wyoming and Nevada (PDMP COE, NFF 1.1, 2.5). This suggests that states, if they are not already doing so, should be encouraged to conduct periodic threshold and other analyses to track trends in possible questionable activity on the part of patients and prescribers that can then be correlated with PDMP utilization and reporting. PDMPs that are Harold Rogers grantees report such analyses every three months. Such analyses may provide evidence suggesting PDMP effectiveness that could be communicated to stakeholders and funders to build support for PDMPs. Developing standard analyses common to all PDMPs, e.g., using validated thresholds and/or criteria for questionable activity (see B.  Determine  valid  criteria  for  possible  questionable activity, above), would permit cross-­‐state comparisons to help evaluate program innovations and provide standard measures by which to gauge the impact of PDMPs over time.

Barriers to adoption: Barriers to conducting periodic analyses of questionable activity include lack of program resources to carry out analyses and the need for standard criteria to permit cross-­‐state comparisons.


Rationale: Periodic analyses of rates of questionable activity track an indicator of possible substance abuse and diversion, and can help assess the impact of the PDMP and program improvements.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: Harold Rogers grantees and some other states conduct regular analyses.

Barriers to adoption: Lack of program resources to conduct analyses, no standard criteria for questionable activity.

D. Conduct epidemiological analyses for use in surveillance, early warning, evaluation, and prevention

Rationale: As part of their standard practice, PDMPs make reports on individual prescription histories available to end users, but some also produce and disseminate other types of data analyses relevant to public health objectives involving prescription drugs. Distributing such analyses, which ordinarily de-­identify or encrypt patient and prescriber-­specific information, may increase the impact of PDMPs. PDMP data can be analyzed by geographic area (county, zip code, pharmacy, town, etc.) and time period to illuminate trends in both prescribing and questionable activity relevant to drug abuse surveillance and prevention efforts. Under its Harold Rogers Grant Program, BJA gives priority consideration to PDMPs proposing to share data and partner with researchers conducting epidemiological analyses concerned with the prescription drug abuse epidemic.

Evidence of effectiveness and current adoption status: Some states have conducted epidemiological analyses of PDMP data for a variety of purposes. Maine’s PDMP provided data on controlled substance prescribing patterns to the National Institute on Drug Abuse’s Community Epidemiological Work Group, which reports on emerging drug abuse trends at the state and city levels (personal communication), and researchers have analyzed Maine PDMP data to describe trends in prescribing and questionable activity (Payne & Thayer, 2009). The South Carolina PDMP provided data to the PDMP COE by county and by age group on the prescribing of opioids; analyses identified an unexpected level of young opioid users in two major counties. This information, along with Wyoming PDMP data on the prevalence of doctor shopping by age group, was provided to the U.S. Surgeon General’s 2011 Expert Panel on Prescription Drug Abuse in Youth (Eadie, 2011, March). Similarly, the Massachusetts PDMP and Brandeis University researchers have produced geo-­‐spatial analyses of rates of possible doctor shoppers. These analyses indicate that communities with the highest rates also tend to have the highest concentrations of opioid overdoses and deaths (Carnevale & Associates and PDMP COE, 2010; Kreiner, 2011). More recent analyses indicate that communities with high rates of questionable activity are at risk for subsequent increases in rates of fatal and non-­‐fatal opioid overdoses (Kreiner, 2012). Had these analyses been possible in prior years, the Massachusetts PDMP could have issued warnings before the overdoses and deaths became epidemic. Warnings could be sent to all community, state, and national stakeholders, including health care practitioners, law enforcement agencies, educators, substance abuse prevention and treatment organizations, schools, parent-­‐teacher organizations, religious organizations, and other groups.

PDMP COE analyses of de-­‐identified data from states neighboring Georgia identified zip codes within Georgia where Georgia prescribers were issuing unusually large numbers of prescriptions for controlled substances (Carnevale & Associates and PDMP COE, 2010). This information enabled Georgia officials to identify possible pill mills within their state borders, even before their PDMP was enacted into state law. These examples suggest that PDMPs are a rich but underutilized resource for surveillance and evaluation efforts aimed at preventing prescription drug abuse and overdose. To assess the range of application of PDMP data beyond providing prescription history reports, states could be surveyed on the types of further analyses they produce and the end users receiving the prescriptions.

Barriers to adoption: Barriers to further analysis and dissemination include lack of PDMP resources; PDMPs' lack of familiarity with such analytical methodologies; the absence of working relationships between PDMPs and state and community organizations that could benefit from access to the analyzed data, e.g., substance abuse prevention groups; and state restrictions on reporting to or collaborating with outside research organizations.


Rationale: Epidemiological analyses can assist in drug abuse surveillance, evaluation, and prevention efforts.

Evidence of effectiveness: Unpublished data analyses.

Current adoption status: Several PDMPs have provided analyses for communities and state agencies.

Barriers to adoption: Insufficient program resources or expertise to carry out analyses, absence of cooperative working relationships between PDMPs and other groups, and restrictions on providing data to researchers.

E.  Develop automated expert systems to expedite analyses and reports

Rationale and evidence of effectiveness: Reliable and valid analysis of PDMP data to identify questionable activity, track prescribing trends, and conduct other research often involves multiple steps and requires familiarity with prescription information (e.g., drug classifications, standard doses, data ambiguities) gained over years of personal hands-­on experience. Automated expert systems that capture at least some of this expertise may increase the speed and accuracy of such analyses and their reporting, freeing up staff time and program resources for other initiatives. Automated systems can also generate unsolicited reports and alerts based on criteria of questionable activity (see B.  Determine  valid  criteria  for  possible  questionable  activity, above). Given that those meeting such criteria sometimes number in the thousands, automated algorithms to reliably identify such individuals and generate alerts to their prescribers and pharmacists may be the only feasible means to conduct proactive reporting on the necessary scale. Research is needed to document existing PDMP expert systems, evaluate their efficiencies, and help develop software programs and standard algorithms that reliably identify probable questionable activity and accelerate other analyses. Given the wide application of expert systems in other public health and safety contexts, it seems likely that PDMPs would gain in effectiveness by
adopting automated procedures in analyzing and reporting their data.

Current adoption status: Some states have explored the design of automated expert systems that can expedite analyses. Massachusetts and Oklahoma are using off-­the-shelf business intelligence software to track prescribing patterns and PDMP utilization. States could be surveyed on what, if any, expert systems and software are being used and their impact on improving PDMP productivity.

Barriers to adoption: These include the limited resources of PDMPs, leaving them without staff, time, or funds to explore such issues; the absence of guidance material or information that PDMP administrators could utilize; design and implementation costs for customized systems; and whether a state’s software vendor (if it has one) has the capacity and flexibility to implement such a system.


Rationale: Expert systems and automated analyses and reports may increase the productivity of PDMPs.

Evidence of effectiveness: Accumulated field experience, key stakeholder perceptions.

Current adoption status: At least a few states have explored expert systems.

Barriers to adoption: Limitations of PDMP resources, absence of information or guidance documents, design and implementation costs, software vendor capacity.

F.  Record data on prescriber disciplinary status and patient lock-­ins

Rationale: PDMPs could enhance their effectiveness if they could obtain and match to prescription records data on prescribers’ deaths or disciplinary status, such as a DEA registration suspension. Upon receipt of prescription information from pharmacies, the PDMP could flag any such prescribers, prompting referral to appropriate agencies. The Government Accountability Office (GAO) found in its 2009 examination of Medicaid programs that state Medicaid agencies paid for prescriptions of controlled substances that were issued by deceased prescribers or those barred from such prescribing, or that were dispensed by pharmacies not legally authorized to do so (GAO, 2009). These forms of diversion could be effectively monitored by PDMPs were they able to link to the relevant databases.

Similarly, information from Medicaid or third-­‐party payers on patients who are in a restricted recipient program or "lock-­in" to a single prescriber and pharmacy could be recorded by the PDMP. If a check of the PDMP indicates the prescription about to be dispensed is not from the specified prescriber and pharmacy, the pharmacist could take steps to make sure that dispensing is appropriate. This would be consistent with GAO’s 2011 recommendation to CMS for the Medicare program that a restricted recipient program be implemented (GAO, 2011). Even if the pharmacist does not detect this prior to dispensing, the PDMP could detect that the prescription was issued and dispensed by an unauthorized prescriber and/or pharmacy and report it to the Medicaid program. Alternatively, the PDMP could make the data available to Medicaid or other third-­party payer so it could analyze the data and identify the violation of a lock-­in, as has Washington State (see User  access  and  report  dissemination,  B.  Optimize  reporting  to  fit  user  needs, below).

Evidence of effectiveness: The potential effectiveness of giving PDMPs access to data on prescriber disciplinary status and patient lock-­ins is suggested by other instances of data sharing that enable identification of problematic prescribing and dispensing, for instance Washington State’s provision of PDMP data to its Medicaid program (see User  access  and  report  dissemination,  B.  Optimize  reporting  to  fit  user  needs, below).

Current adoption status: No PDMPs were found that record prescriber disciplinary status or patient lock-ins.

Barriers to adoption: To link to the relevant databases and flag reports, PDMPs will have to implement data-­sharing agreements and develop the necessary information systems. Limited program resources pose the biggest obstacle to such development.


Rationale: Dispensers could check the PDMP for data on practitioner disciplinary status and patient lock-­ins to ensure that the presented prescription is advisable to dispense.

Evidence of effectiveness: Key stakeholder perceptions.

Current adoption status: None.

Barriers to adoption: Lack of resources needed to develop systems to record data and automatically flag practitioners and patients when the PDMP is queried. 

User access and report dissemination

Best practices in PDMP access and reporting will maximize the availability and utility of PDMP data to the widest range of appropriate end users. Candidate practices include actions to:

A. Provide continuous online access and automated reports to authorized users

B. Optimize reporting to fit user needs

C. Integrate PDMP reports with health information exchanges, electronic health records, and pharmacy dispensing systems 

D. Send unsolicited reports and alerts to appropriate users

E. Publicize use and impact of PDMP via websites, presentations, and reports 

A.  Provide continuous online access and automated reports to authorized users 

Rationale: PDMPs began as paper-­ or faxed-­based systems, distributing custom-­generated reports to limited numbers of users, mostly on request (solicited reports). Since the advent of electronic databases, many states have moved to automated online systems that make prescription history reports continuously available to authorized and authenticated users at their computer terminals. This is important since medical care is provided by emergency departments, and
dispensing is provided by some pharmacies 24 hours a day, seven days a week, year-­round.

Evidence of effectiveness: Anecdotal reports and some observational evidence suggest that ease of access to the PDMP encourages its utilization, increasing the number of data queries far beyond what earlier systems envisioned. As its reports are made more widely available to end users, a PDMP’s impact appears to increase. Data from Virginia's PDMP show a typical pattern: As the state enabled continuous online access and automated reporting beginning in 2010, data queries, mostly by prescribers, jumped from 75,432 in 2009 to 433,450 in 2010. Simultaneously, and possibly because of
this increased PDMP utilization, the number of individuals in the PDMP database meeting 10x10 and 15x15 over six-­month thresholds for doctor shopping declined (Virginia Prescription Monitoring Program, 2010). Continuous online access also encouraged Virginia medical examiners to make PDMP reports a standard element of all case investigations, enabling more efficient determinations of cause of death (PDMP COE, NFF 2.6).

Another example is the new Florida PDMP, which first allowed prescribers and pharmacists to request data online on October 17, 2011. Within the first 10 weeks (as of December 31, 2011), 337,635 patient-specific controlled substance dispensing queries had been performed by prescribers and pharmacies, providing information for safe prescribing and dispensing (Florida PDMP data). Given the tremendous increase in use afforded by online access, it is a high priority for states to move to automated systems that make prescription history data continuously available to end users.

Current adoption status: Currently, all but four states have established or are installing online databases with Web portals for prescriber and pharmacist inquiries. The following states implemented Web portals or online access during 2011 and early 2012: Alaska, Florida, Massachusetts, Oregon, and Washington (PDMP COE Survey of PDMPs, 2011, and communication with Washington State PDMP).

Barriers to adoption: Barriers to implementing such systems include cost, concerns about data security, and information technology bottlenecks.


Rationale: Continuous online access seems to increase use and impact of a PDMP.

Evidence of effectiveness: Unpublished Virginia PDMP data, Florida PDMP data, case study.

Current adoption status: Most PDMPs.

Barriers to adoption: Cost, technological bottlenecks, data security concerns.

B.  Optimize reporting to fit user needs

Rationale: Besides making reports continuously available, PDMPs are beginning to explore reporting functionalities and formats that will further incentivize use of their data by meeting the needs of end users. PDMP reports can be tailored to specific types of end users, for example by highlighting or suppressing certain data fields for law enforcement investigators, or by providing reports of particular interest to licensing boards. Best practices in reporting will be those that best meet end-user requirements.

Current adoption status and evidence of effectiveness: The Massachusetts PDMP plans to enable batch reporting as part of its new online system, allowing prescribers to retrieve automated summary prescription histories for all patients scheduled for upcoming appointments. A full report for any patient can then be downloaded if necessary. The Washington State PDMP has agreed to provide batch transfer of PDMP data to Medicaid for its enrollees, to the Workers’ Compensation unit in the Department of Labor and Industries for workers’ compensation claimants, and to the Corrections
Department for inmates. A review of Washington PDMP data for Medicaid enrollees identified more than 2,000 individuals in 2012 receiving Medicaid and cash-­‐paid prescriptions for controlled substances on the same day. It also found 478 clients for whom cash and Medicaid prescriptions for the same drug were filled less than 10 days apart and from a different prescriber. (Presentation by Scott Best, Clinical Nurse Advisor, Washington State Health Care Authority at CDC Medicaid Patient Review and Restriction Expert Panel Meeting, August 27-28, 2012, Atlanta, GA). Without the batch transfer of PDMP data, this activity would not have come to light.

PDMPs should be surveyed to document the types of PDMP report customization they currently offer, as well as any innovative reporting functions. To gauge effectiveness, process outcome data on how changes in reporting affect utilization should be sought from PDMPs as well as survey data from end users on the usefulness of customized reports or functionalities. Such information could help determine which of these might be recommended as PDMP best practices in reporting.

Barriers to adoption: Barriers to optimizing reports for end users include the costs of designing and implementing customized report types as well as the need to survey end users on what report types and functionalities would be most useful.


Rationale: Meeting end-­user needs by optimizing reporting helps incentivize use of PDMP data, increasing PDMP impact.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: A few PDMPs.

Barriers to adoption: Development and implementation costs of new reporting functions and customizations.

C.  Integrate PDMP reports with health information exchanges, electronic health records, and pharmacy dispensing systems

Rationale: Integrating PDMP data retrieval with health information exchanges (HIE), electronic health records (EHR), and pharmacy dispensing systems should help reduce the time and effort needed for prescribers and their staff and for pharmacists to access a patient’s prescription history. The Office of the National Coordinator for Health Information Technology (ONC) at the Department of Health and Human Services, in collaboration with MITRE Corporation, is leading an effort to develop and test a methodology for seamless transfer of PDMP data to prescribers, dispensers, and emergency departments before patients are seen by physicians and to pharmacies before dispensing. This effort, called “Enhancing Access to PDMPs,” plans to utilize systems in which health care providers and third-party payers confirm patients' eligibility for third-­‐party payment prior to patients being treated. The ultimate goal is to provide secure PDMP data in real time to electronic records systems such that medical providers have continuous access to prescription history information vital to safe prescribing of controlled substances.

Current adoption status and evidence for effectiveness: Two pilot projects are planned by the ONC, one in Ohio using a “drug-­‐risk indicator” in the EHR, and one in Indiana involving emergency department staff access to prescription information via EHRs. These efforts, and other initiatives by states to incorporate PDMP data into HIE/EHR, need to be documented and evaluated to determine their feasibility and which of them show promise as models for other states. In advance of full integration with health information systems, intermediate steps to integrate the PDMP into the provider’s
workflow can be explored, such as instituting batch reporting on patients scheduled for upcoming visits (see B.  Optimize  reporting  to  fit  user  needs, above) and sending unsolicited reports or alerts to prescribers and dispensers that prompt them to consult the PDMP (see D.  Send unsolicited  reports  and  alerts  to  appropriate  users, below).

Barriers to adoption: Barriers to integrating PDMP reports with health information exchanges and electronic medical records include the need to develop and test data systems, and concerns about data security and patient confidentiality.


Rationale: Integrating PDMP data with HIEs, EHRs and pharmacy dispensing systems facilitates prescriber and dispenser access to PDMP data.

Evidence of effectiveness: Key stakeholder perceptions.

Current adoption status: None.

Barriers to adoption: Lack of resources needed to develop and test data systems, concerns about data security, and patient confidentiality.

D. Send unsolicited reports and alerts to appropriate users

Rationale: Some PDMPs, in addition to supplying reports when requested or downloaded by end users (solicited reports), also send out unsolicited reports based on PDMP data suggesting questionable activity such as doctor shopping or inappropriate prescribing such as by pill mills. Recipients of unsolicited reports sent by states include prescribers, pharmacists, investigative agencies, and licensure boards. As a minimum requirement for states to receive PDMP funding under NASPER, SAMHSA established that PDMPs must provide unsolicited reports to medical practitioners (SAMHSA,
2005). Unsolicited reports can serve several functions: inform prescribers and pharmacists that patients may be abusing or diverting controlled substances; help prescribers make better decisions about prescribing controlled substances, thus improving patient care; and inform potential end users about the PDMP and its value. Reports sent to investigative agencies and licensure boards can assist in targeting drug diversion reduction efforts and ensuring safe, effective, and legal medical practice.

Evidence for effectiveness: Nevada initiated its PDMP in 1997 by sending unsolicited reports to prescribers about possible doctor shoppers. These reports quickly generated interest in the PDMP among prescribers, sparking further requests for data (solicited reports) (PDMP COE, NFF 2.5). Analyses of Nevada PDMP data from 1997 to 2002 indicate that individuals for whom unsolicited reports were sent exhibited declines in the average number of dosage units and numbers of pharmacies and prescribers visited subsequent to the reports. This suggests the reports may have
influenced prescribing by providers treating these patients. Similarly, analyses of data from the Wyoming PDMP suggest that unsolicited reports helped to raise awareness of the PDMP, leading to greater requests for data, with a subsequent decline in numbers of individuals identified in the PDMP database who met doctor shopping thresholds (PDMP COE, NFF 1.1).

Preliminary data from a Massachusetts survey of prescribers receiving unsolicited reports indicate that just 8 percent were aware of all or most of the other prescribers listed on the reports, and only 9 percent judged that the prescriptions listed were medically necessary (MADPH Advisory Council Presentation, 2012). Pharmacists and prescribers in Maine who received automatic threshold reports on patients took a variety of actions in response, including discussing reports with patients, calling pharmacists who had dispensed to the patient, establishing a controlled substances agreement,
conducting a substance abuse screening and brief intervention, and referring patients to substance abuse treatment (Sorg et al., 2009). These findings suggest that unsolicited reports can serve important functions in providing new information to practitioners and guiding their clinical practice. A cross-­state evaluation of PDMPs by Simeone and Holland indicated that states with PDMPs that engaged in unsolicited reporting reduced sales of controlled substances by 10 percent
compared to states without PDMPs, potentially reducing diversion and abuse (Simeone & Holland, 2006).

Further studies are needed to determine the impact of unsolicited reporting and the mechanisms by which such reporting influences doctor shopping and prescribing behavior, especially studies involving matched comparison groups of individuals for whom unsolicited reports are not sent. Unsolicited reports can also prompt regulatory boards to determine if providers are operating outside of accepted standards of care. Guidelines for appropriate reporting to boards need to be developed, taking into account current practices by the states that permit such reporting.

An apt model for unsolicited reports and their use is the well-­established public health practice of mandated reporting to disease registries operated by state health departments. Such registries include communicable diseases like mumps, rubella, and tuberculosis; positive HIV diagnoses; cancer; and other chronic diseases. Such registries are regularly analyzed, and proactive public health interventions are initiated when outbreaks or epidemics are detected.

While some persons who obtain controlled substances from multiple prescribers and dispensers do so in order to resell the drugs on the street, others obtain excessive drugs for abuse, meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM)-­‐IV criteria for abuse or dependence. Analysis by researchers in Washington State indicates that individuals who consume 100 morphine milligram equivalents or more per day are eight times more likely to overdose than persons consuming lesser quantities (Dunn, 2010). The proactive analysis of PDMP data and distribution of
unsolicited reports to help prevent such overdoses would constitute a public health intervention, just like that of other disease registries. In its 2012 Harold Rogers Grant Program solicitation, BJA stated it would give priority consideration to PDMPs proposing to carry out unsolicited reporting.

Current adoption status: As of a survey of 38 states in November 2011, 30 PDMPs are authorized to provide unsolicited reports to providers, but only 16 of them were actually doing so. A smaller number were also providing such reports to law enforcement agencies (eight PDMPs) and licensing boards (seven PDMPs) (PDMP COE Survey of PDMPs, 2011). Mississippi now sends unsolicited reports to individuals whose prescription histories suggest questionable activity, then tracks their prescription behavior using PDMP data. Indiana has instituted “user-­led” unsolicited reports: A practitioner who has retrieved PDMP data suggestive of a patient’s questionable activity is enabled to send notifications to other practitioners concerning the patient. These innovative approaches to unsolicited reporting could be evaluated as possible best practices.

Instead of sending full reports containing patient data, some states send letters or alerts to providers, notifying them that one or more of their patients (identified by a coded number) might be doctor shopping, and recommending that they view PDMP data on the patient. If they are not registered with the PDMP, they can open accounts to access the data. Louisiana has instituted an automated system of generating alert letters to practitioners, minimizing costs and increasing the
rate of notification, and Massachusetts is developing a similar system. Given that persons identified as possible doctor shoppers in PDMP databases can number in the thousands, depending on the thresholds or criteria used, automated methods for notifying prescribers seem indicated but are in need of evaluation.

Barriers to adoption: Barriers to issuing unsolicited reports include PDMP-­enabling legislation in some states that does not authorize such reporting, lack of staff and information system resources needed to analyze PDMP data to detect questionable activity and to generate and disseminate reports, and a concern expressed by some that unsolicited reports will de-­incentivize prescriber-initiated access to the PDMP (even though available information cited above indicates
the opposite effect). See Section  V.  Summary  and  Recommendations for recommendations for research and development of  best practices related to unsolicited reporting.


Rationale: Unsolicited reports proactively inform end users about the PDMP and of possible doctor shopping, inappropriate prescribing, and drug diversion; help inform safe and effective prescribing and dispensing; and incentivize enrollment and use of PDMP.

Evidence of effectiveness: Published study, case studies, unpublished survey data, expert opinion.

Current adoption status: Thirty PDMPs are authorized to provide unsolicited reports, and 16 actually do so.

Barriers to adoption: Legislative prohibitions, lack of program resources.

E.  Publicize use and impact of PDMP via websites, presentations and reports, and analyses

Rationale and evidence of effectiveness: A few PDMPs are proactive in publically disseminating selected findings from their analyses and end-­user outcomes via websites, presentations and reports. Many, but not all, PDMPs maintain public websites that are or could be used to publicize reports and findings. Greater public outreach on the part of PDMPs could raise awareness about the prescription drug abuse epidemic and the role PDMPs can play in its mitigation, which in turn could build support for funding their operations. For example, reports making the connection between PDMP activity and declines in doctor shopping and inappropriate prescribing would likely increase the positive perception of prescription monitoring as an effective tool in mitigating drug diversion and abuse. PDMP data on prescribing patterns is also of great interest to those interested in public health, whether for personal or professional reasons, so making it available constitutes a valuable public service. In order to give PDMP stakeholders and the public a wider understanding of the prescription drug abuse epidemic and PDMPs' roles in addressing it, states' websites could link to the websites of the PDMP Training and Technical Assistance Center and the PDMP COE. A survey of PDMP practices in this area would help identify effective approaches to public education and the sorts of reports and analyses that are appropriate for release and most influential in increasing PDMP awareness.

Current adoption status: States vary to the extent to which they proactively disseminate findings and outcomes related to PDMP data and activities to the wider public. A majority of PDMPs have websites (list available at­‐pmp-­‐websites) that give an overview of program objectives and operations but are largely configured to accommodate authorized PDMP users. However, a few programs also make data analyses available. For example, Maine offers recent PDMP news and an epidemiological evaluation of PDMP data from 2005 to 2008 (, and Virginia posts reports showing increased PDMP utilization and concomitant declines in doctor shopping rates
( Others, such as
Kentucky, link to satisfaction surveys that document the valuable role PDMPs play in clinical practice, and to regular (e.g., quarterly) reports that show prescribing patterns by geographic area, for instance the mostly widely prescribed drugs in each county.

Barriers to adoption: Barriers to publicizing PDMP data and activities include resource limitations in generating data analyses, disseminating reports, and in expanding, updating, and maintaining websites.


Rationale: Raising awareness of PDMPs via websites, presentations, and reports may help build support and help ensure funding.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: Some PDMPs publicize findings via data summaries and reports via public websites and other outlets.

Barriers to adoption: Lack of staff resources to produce and disseminate reports, maintain websites.

PDMP recruitment, utilization, and education

Best practices in recruitment, utilization, and education will maximize participation in a PDMP by all appropriate users. They will also promote understanding the value and application of PDMP data in prescribing and dispensing, drug diversion investigations, drug abuse prevention programs, planning and siting drug treatment programs and office-­based opioid treatment; and other activities that address prescription drug abuse. Candidate practices include actions to:

A. Enable access to PDMP data by all appropriate users; encourage innovative applications

B. Outreach and recruitment strategies

  1. Proactively identify and conduct outreach to potential high-­impact users
  2. Conduct recruitment campaigns
  3. Streamline certification and enrollment processing
  4. Mandate enrollment

C. Approaches to increasing utilization

    1. Conduct promotional campaigns
    2. Improve data timeliness and access
    3. Conduct user education
    4. Mandate utilization
    5. Institute financial incentives
    6. Delegate access

A.  Enable access to PDMP data by all appropriate users; encourage innovative applications

Rationale and evidence of effectiveness:  PDMPs differ in their data access policies, sometimes making it difficult for potential users to access PDMP data, such as health professional licensing boards and law enforcement investigators. Some PDMPs selectively bar access to their data altogether by not expressly authorizing access for substance abuse treatment programs and professionals, medical examiners, Medicaid and Medicare agencies, workers' compensation programs, and other third-party payers. Such restrictions can limit the effectiveness of PDMPs in helping to improve prescribing and in curtailing prescription drug abuse. PDMPs can therefore increase their effectiveness by seeking to widen access to their data by all legitimate users, making sure sufficient safeguards and training are in place to maintain confidentiality of prescription records, and prevent misuse of patient and prescriber information.

BJA gives priority consideration for funding under its Harold Rogers Grant Program to PDMPs proposing to widen data utilization. In particular, local, state, and federal law enforcement agencies and investigators should be given case-­appropriate access to PDMP reports (PDMP COE, NFF 2.3). California and Texas, which have long provided both unsolicited and solicited reports to law enforcement agencies, and New York, which has provided such reports to narcotic enforcement investigators within the Department of Health, have lower than average death rates from
unintentional opioid overdoses (Eadie, 2011b; Paulozzi, 2010). To help curb prescription forgeries and theft, prescribers could be encouraged to consult PDMP databases periodically to ensure that their DEA controlled substance number is not being used surreptitiously (self-­lookup).

To maximize end-­user participation, PDMPs first need to identify which types of potential users are overly limited or barred from using PDMP data and those who are simply unaware of the PDMP. They can then undertake initiatives to enable such use, such as legislative and/or regulatory reform or outreach to agencies or professional organizations.

In addition, PDMP stakeholders should be encouraged to promote innovative applications of PDMP data, along with evaluations of their effectiveness. New applications, perhaps involving new categories of users, may eventually become best practices that states can adopt in realizing the full potential of PDMPs.

Current adoption status: Depending on the state, PDMP end users typically include prescribers, dispensers, medical licensing boards, and law enforcement investigators. Some PDMPs, however, have widened their user base to include medical examiners, drug treatment programs and treatment professionals, criminal justice diversion programs such as drug courts, "pre-­criminal" intervention programs (PDMP COE, NFF, 2.1), and drug prevention initiatives (PDMP COE, NFF 3.2). Washington State's new PDMP provides data to Medicaid, the Workers' Compensation unit in the Department of Labor and Industries, and the Corrections Department (communication from PDMP administrator). A 2012 statute authorizes the New York State PDMP to provide data to local health departments for purposes of public research and education. Other categories of users could include health care systems' peer review organizations (the North Dakota PDMP is authorized to provide data to peer review organizations) and third-party payers' health care professional reviewers.

PDMPs with more inclusive data access policies can serve as models for programs seeking to expand their user base. For example, Kentucky’s PDMP permits use of its data by drug diversion investigators (PDMP COE, NFF 2.3) and drug courts (PDMP COE, NFF 2.4), Virginia’s by medical examiners (PDMP COE, NFF 2.6), and other states by outpatient drug treatment programs (PDMP COE, NFF 2.2). A compilation of all appropriate end users, developed in consultation with state PDMPs and the PDMP Training and Technical Assistance Center, would provide direction in maximizing appropriate use of PDMP data. Developing case studies of how data are applied by these end users and in innovative applications (see the  PDMP  COE  “NFF”  series) will also assist in moving this process forward.

Barriers to adoption: Barriers to permitting greater access to PDMP data include the absence of specific authorization for certain users written into a state’s enabling PDMP legislation and/or regulations; concerns of prescribers and pharmacies about professional licensing boards or law enforcement agencies being able to see information about their prescribing and dispensing behavior (sometimes described as fear of so-called "fishing expeditions" by investigators); concerns about revealing the identity of patients in drug treatment programs; lack of PDMP resources to undertake outreach and legislative initiatives; and lack of awareness of PDMPs on the part of potential end users.


Rationale: Permitting and encouraging use of PDMP data by all appropriate users, and in innovative applications, will help to maximize PDMP utilization and impact.

Evidence of effectiveness: Case studies.

Current adoption status: States vary in restricting or encouraging use of PDMP by different categories of users.

Barriers to adoption: Legislative prohibitions on PDMP data access by potential users, concerns about misuse of data by law enforcement and substance abuse treatment agencies, lack of awareness of PDMP.

B.   Outreach and recruitment strategies

Enrollment in and use of PDMPs by medical practitioners is key to achieving their full potential in helping to ensure safe prescribing and dispensing, and in reducing diversion and abuse of controlled substances.

One of the most significant challenges facing PDMPs has been the slow increase in enrollment in and use of PDMPs by prescribers and pharmacists. Rates of enrollment among prescribers are well below 50 percent in most states.4  Best practices, therefore, need to be identified for how PDMPs can most efficiently increase enrollment among user groups, including producing enrollments of, for example, at least 50 percent of those who wrote 10 or more controlled substance prescriptions in the past year, or of prescribers of at least 50 percent of prescriptions written.

To inform best practices in this domain, appropriate rates of enrollment need to be studied, taking into account that many providers prescribe infrequently and that a relatively small proportion of prescribers are responsible for issuing most controlled substance prescriptions. Data from the Massachusetts PDMP indicate that just 30 percent of all those who prescribed an opioid at least once in 2011 were responsible for 88 percent of all opioid prescriptions in 2011 (MADPH Advisory Council Presentation, 2012).  This suggests that to maximize the effectiveness of PDMPs, recruitment strategies could profitably be focused on the most frequent prescribers of those controlled substances implicated in abuse and diversion (see immediately below).

1. Proactively  identify  and  conduct  outreach  to  potential  high-impact  users    

Rationale and evidence for effectiveness: Certain categories of potential PDMP users are a high priority for enrollment given the impact their use of PDMP data would likely have in improving prescribing and dispensing, and in reducing diversion and abuse of prescription drugs. Primary among these are the most frequent prescribers of controlled substances, such as the top 10 percent in terms of prescriptions per year (Paulozzi, 2011), as well as those prescribers with relatively high proportions of suspected doctor shoppers in their practices. Such prescribers are readily
identifiable using PDMP data and can be encouraged to enroll in and use the PDMP via letters and alerts, either  electronically or by mail.

In 2010, Utah’s PDMP analyzed its data to identify top prescribers, then contacted them electronically, resulting in a rapid rise in enrollment among this group. Massachusetts is currently conducting an initiative to identify prescribers with relatively high proportions of doctor shoppers in their practices; these prescribers are receiving letters suggesting they join and use the Massachusetts PDMP. These prescribers’ enrollment in and utilization of the PDMP will be monitored, along with any changes that may occur in the proportion of possible doctor shoppers in their practices.

Current adoption status: Contact with other PDMPs is warranted to ascertain which are engaged in similar efforts and assess outcomes, including on enrollment, utilization, prescribing, doctor shopping rates, and proportions of doctor shoppers among identified frequent prescribers. Outreach to frequent prescribers for enrollment in the PDMP will need to be coordinated with licensure boards and investigative agencies in case any of the identified practitioners happen to be subjects of disciplinary action or investigations.

4 - According to data during the first half of 2010 from Harold Rogers PDMP Grant Program, of 12 PDMPs with operational online Web portals for prescribers to request prescription history reports, 11 reported 9 to 39 percent of prescribers who issued controlled substances prescriptions were registered. Only one state (Hawaii) reported 100 percent registration.

Barriers to adoption: Barriers to adoption include the limited resources of PDMPs, leaving them with limited staff, time, or funds to conduct outreach to high-­‐frequency prescribers and other target groups.


Rationale: Recruiting high-frequency prescribers may help to maximize impact of PDMP in improving prescribing, reducing doctor shopping.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: A small number of states have targeted potential high-­impact users.

Barriers to adoption: Lack of program resources to identify and conduct outreach to target groups.

2. Conduct recruitment campaigns  

Rationale and evidence for effectiveness: In launching and promoting their PDMPs, most states conduct recruitment campaigns to raise awareness of the PDMP and enroll participants. Virtually all PDMPs engage in one or more forms of recruitment, including a mix of presentations to professional groups, hospitals, and conferences; mail and e-mail campaigns; online training modules and webinars; and Web pages with instructional materials and FAQs. Recently, a few states have initiated targeted outreach to potential high-­impact users (see 1. Proactively identify  and conduct outreach to potential high-­impact users, above). Campaigns have included disseminating end-user testimonials about the value of PDMP data, such as those gathered by surveys of PDMP users in Kentucky (Kentucky Cabinet for Health and Family Services, 2010). Some states, such as Massachusetts, take advantage of controlled substance registration requirements to
notify prescribers about the PDMP and facilitate enrollment.

Little data exist on the relative effectiveness of various recruitment strategies. To help inform best practices, states' promotional activities should be examined in connection with how they affect rates of enrollment. Historical data on activities and enrollment rates are often available to PDMPs; these could provide some indication of the impact of specific promotional efforts, or types of efforts, as reflected in applications to join the PDMP.

Current adoption status: States that have recently conducted outreach campaigns, or that are in the process, include Massachusetts, North Carolina, Utah, and Vermont. Surveys of both enrolled and non-­enrolled practitioners could shed light on which recruitment techniques seem to achieve the most penetration, and which barriers exist to learning about and joining the PDMP. A recent survey found that a significant deterrent to enrollment among pharmacists in Ohio was the perceived time needed to access a PDMP report (Ulbrich et al., 2010). This suggests that educating prospective
PDMP participants about the advantages and ease of access to PDMP data would help increase enrollment.

Barriers to adoption: States' resources are limited, especially during this difficult economic period, including funding for activities to recruit participants. Moreover, little evidence exists on the relative effectiveness of recruitment strategies, so programs lack guidance on how to proceed in outreach efforts.


Rationale: Well-focused recruitment campaigns may boost PDMP enrollment. Evidence of effectiveness: Accumulated experience, key stakeholder perceptions. Current adoption status: States have undertaken a variety of recruitment campaigns.

Barriers to adoption: Lack of resources, little evidence on what approaches produce best enrollment outcomes.

3. Streamline  certification  and  enrollment  processing 

Rationale and evidence for effectiveness: Among the barriers to enrollment in a PDMP is the sometimes burdensome process of certifying a potential user’s credentials and establishing secure system access via proper identification, including passwords and biomarkers. Evidence-based best practices in user certification and enrollment would streamline and automate these processes, while maintaining confidentiality and system security. For example, requiring notarization of prescribers' applications for PDMP accounts, although helping to validate an applicant's identity, may present an obstacle to enrollment for busy practitioners. Further investigation of notarization and alternative means of validating identity and credentials is warranted. This is especially important, since without notarization, it would not be difficult for someone to fraudulently claim to be a licensed prescriber or pharmacist, open a PDMP account, and then obtain confidential data that could be used against others, e.g., against a rival in a divorce or domestic custody suit or
against an opposing candidate running for political office. Given that a few states have reported such fraudulent activity, this must be examined carefully. Experience in some states, described below, suggests that enrollment and authentication procedures can be safely automated, but long-term data on fraudulent enrollments and security breaches need to be collected to confirm this hypothesis.

Current adoption status: Utah, which mandates prescriber enrollment in its PDMP (see 4.  Mandate enrollment, below), has taken advantage of its cross-­agency integration of health provider information to expedite PDMP certification and enrollment. Kentucky, also in response to a utilization mandate, has developed application forms that prescribers can complete online, submit electronically, and simultaneously print for notarization and submission. Connecticut has developed a process through which applicants need not send in paper forms, even after notarization; instead, applicants submit forms by fax, and the PDMP's computers automatically convert the forms to electronic files. Florida’s enrollment and authentication procedures are fully automated, involving electronic communication between an online application form and a Department of Public Health database. Such approaches could serve as models for other states for how to incentivize and process enrollments, should evaluation confirm their security and efficacy. A survey of other PDMP
enrollment procedures could help identify those that minimize the time and inconvenience for potential participants. Enrollment data from PDMPs can help validate hypotheses about which procedures are most effective in accelerating the enrollment process. There is also a need to study the feasibility of using the federally required certification of
prescribers to authorize their electronic prescribing of controlled substances prescriptions. States could potentially use the federal certification to accept and enroll users in their PDMPs, thus saving the prescriber from duplicative authentication procedures and expediting the PDMP enrollment procedure. This kind of study is urgent as e-­prescribing of controlled substances is expected to advance quickly, especially as New York State has passed a 2012 statute mandating e-­prescribing of controlled substances within a few years.

Barriers to adoption: Barriers to streamlining certification and enrollment processing include lack of secure online information systems that can replace in-­‐person notarization as a means to authenticate applicants. In particular, the need exists to explore federal certification of prescribers to issue electronic prescriptions for controlled substances, as a shortcut in state authentication systems.


Rationale: Streamlined certification and enrollment processes may increase enrollment and utilization.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: A few states have explored various steps in streamlining enrollment.

Barriers to adoption: Lack of information systems and validated processes that would facilitate certification and enrollment, including possible use of federal certification of prescribers for electronic prescribing.

4. Mandate  enrollment  

Rationale: In most states with operational PDMPs, enrollment and utilization are voluntary. This makes it necessary for states to conduct recruitment campaigns to increase awareness of the PDMP and induce prescribers and pharmacists to enroll (see 2.  Conduct  recruitment  campaigns, above). Such campaigns can be expensive, resource-­intensive, and time-­consuming; PDMP administrators frequently report that campaigns fail to produce high rates of participation. Another option, not yet widely adopted but gaining in prevalence, is to make enrollment in a PDMP mandatory for certain user groups, such as prescribers and dispensers (NAMSDL, 2012a).

Evidence of effectiveness: The effectiveness of prescriber-­and pharmacist-­mandated enrollment in producing greater utilization of PDMPs needs to be assessed, taking into account any unintended consequences, such as resistance on the part of some doctors to a perceived regulatory burden and/or infringement on their autonomy, or the inability of enrollment and certification systems to handle a surge of applications. One PDMP has expressed concern about a legislative mandate for enrollment because it may not provide funding for processing applications. Examining states'
experience could shed light on whether mandates are more successful than voluntary campaigns in producing high rates of enrollment and utilization, and if so, which ancillary systems and policies enable successful mandates. Utah, with a relatively small number of prescribers, has been able to implement mandated enrollment using its advanced health management information system. How and whether larger and less technologically advanced states could carry out such a mandate are open questions needing investigation.

Current adoption status: Since 2007, Arizona has required that practitioners who possess a registration under the U.S. Controlled Substances Act must also be registered with the PDMP. Utah has recently (July 2010) mandated that prescribers join its PDMP, making enrollment a prerequisite for practitioners to renew their federal or state licenses to prescribe controlled substances. More than 90 percent of those with licenses to prescribe controlled substances in Utah are now enrolled in its PDMP (personal communication from Utah PDMP administrator). Similarly, Minnesota requires PDMP enrollment for pharmacists as a precondition for license renewal, and in Louisiana, recent legislation requires the medical directors of pain clinics to enroll in and use the PDMP. Kentucky, New Hampshire, Tennessee, and Massachusetts have passed laws in 2012 mandating registration and use of the PDMP by prescribers (NAMDSL, 2012a and 2012b, communication with Massachusetts PDMP). A New York 2012 statute (the "I-­Stop" Program Bill #39, introduced in June 2012) mandates use of the PDMP prior to prescribing or dispensing controlled substances, with limited exceptions — effectively mandating enrollment as well. A 2012 Massachusetts statute mandates that all prescribers of controlled substances enroll in the PDMP program over a three-­year period as they establish or renew their state controlled substances registrations. Maine requires registration but not utilization.

Barriers to adoption: Barriers to mandating PDMP enrollment include the need for possibly significant revisions in PDMP legislation and regulations, possible opposition from provider groups wary of state intrusion on medical practice, and lack of funding and other program resources to support implementation. A facilitating factor might include the perception that prescriber use of a PDMP is becoming a "duty of care," given its role in promoting safe prescribing, especially as online PDMP reports become available to practitioners.5  This suggests that public and provider education about the value of PDMP data for medical practice might help build support for enrollment mandates, should a consensus emerge that they constitute a best practice for building PDMP participation. See Section V. Summary and Recommendations for further discussion of mandates to enroll in and use PDMPs.


Rationale: Mandating enrollment may increase provider utilization of a PDMP. Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: A few states mandate enrollment.

Barriers to adoption: Need for legislative/regulatory change, provider resistance to mandates, and lack of program resources to implement mandate.

5 - Concerns among doctors that they would become legally liable for failure to consult the PDMP could perhaps be offset by reductions in malpractice insurance premiums for physicians who integrate use of the PDMP into their practices (see 5. Institute financial incentives, below).

C. Approaches to increasing utilization

Like enrollment, actual use of the PDMP — such as requesting a report via fax or accessing an online database – is optional for prescribers and pharmacists in most states. This raises the question of which strategies work best to increase voluntary utilization by registered users and the further question of whether mandating the use of a PDMP might constitute a best or promising practice. Even in states with comparatively well-established PDMPs, awareness of and enrollment in a PDMP do not always entail its utilization (Feldman et al., 2011). 

1. Conduct  promotional  campaigns    

Rationale and evidence for effectiveness: As noted above, states have undertaken outreach initiatives to inform practitioners and the public about the benefits of consulting the PDMP to help assure safe prescribing and dispensing. They have also sought to provide reassurances about patient privacy and explain that fears about the so-­called chilling effect (unwarranted reductions in prescribing pain medication as a consequence of prescription monitoring) may be
overblown. Published data are scarce on the impact of consulting a PDMP on prescribing, but a recent study of emergency physicians indicated that when informed of a patient’s prescription history, they prescribed more controlled substances for some patients but less for others, when compared to their not being informed of patient histories (Baehren et al., 2010). A Canadian study found no significant differences in changes in opioid dispensing rates between provinces with and without PDMPs (Fischer et al., 2011). Dissemination of these and any similar findings that eventually come to light might encourage PDMP utilization by allaying prescribers’ concerns about intrusive monitoring of their medical practice and any chilling effect this might have (Barrett & Watson, 2005; Twillman, 2006; Fornili & Simoni-­Wastila, 2011). Further study is needed to understand how utilization of PDMP data influences prescribing decisions.

The impact of promotional campaigns on utilization will be reflected in the number of data queries to the PDMP, comparing the periods before and after the campaigns, although controlling for confounding factors may prove difficult. Recent data analyses from Virginia suggest that a well-focused outreach campaign, along with program improvements, can increase both enrollment and utilization by prescribers and dispensers (Virginia Prescription Monitoring Program, 2010). It is likely that other states could produce similar analyses to help evaluate the effectiveness of their campaigns. 

Current adoption status: As noted above (see 2.  Conduct  recruitment  campaigns), states have mounted a variety of promotional efforts to recruit PDMP users and educate them concerning the use and value of PDMP data. Massachusetts has mandated prescriber education for the prescribing of controlled substances; such education includes information on how to download and interpret prescription history data (communication with Massachusetts PDMP). For more on prescriber education, see 3.  Conduct  user  education, below.

Barriers to adoption: Scarce resources for PDMPs and prescriber education limit the reach of efforts to increase PDMP utilization.


Rationale: Increasing awareness of a PDMP and the value of its data by means of promotional campaigns and prescriber education may increase utilization.

Evidence of effectiveness: PDMP data showing increased utilization following a campaign.

Current adoption status: Many states conduct campaigns, varying in their characteristics; at least one state mandates prescriber education on prescribing controlled substances, including on use of PDMP data.

Barriers to adoption: Lack of resources for outreach and prescriber education.

 2. Improve data timeliness and access  

Rationale: Experience from states suggests that improving the timeliness and accessibility of PDMP data encourages utilization. Moving from a paper-­ or fax-based system to continuous online access, as all but four PDMPs have done (efforts are under way in those four states to establish online systems), dramatically increases the ease and probability of providers making voluntary queries or solicited reports to the system.

Evidence of effectiveness and current adoption status: In Virginia, initiating round-­the-clock access to PDMP data with auto-response software in 2010, along with a promotional campaign (see 1.  Conduct  promotional  campaigns, above), resulted in a sharp rise in user registrations and data requests (Virginia Prescription Monitoring Program, 2010). It also encouraged Virginia medical examiners to include use of PDMP data in their routine practice (PDMP COE, NFF 2.6). Similarly, as Massachusetts implemented the first phase of its online PDMP starting in 2010, prescribers and dispensers joined and utilized the system in increasing numbers. Another program improvement that may spur greater utilization is shortening the required reporting interval for pharmacies. Shortening the interval to daily or making it available in
real time, as recently implemented in Oklahoma, makes prescription histories more up-­to-date, increasing their value for end users and incentivizing utilization (PDMP COE, NFF 3.1, and see Data collection and data quality, B. Reduce  data collection interval;  move  toward real-time data collection, above). Oklahoma will be tracking the user response to its
real-­‐time reporting initiative, so some quantitative measure of the impact of this program improvement on utilization will be forthcoming. A survey of other states' histories of program improvements, correlated with quantifiable changes in PDMP utilization, would identify the types of improvements that best enable and incentivize use of PDMPs.

Barriers to adoption: The primary obstacle to improving data access is lack of program resources to develop an online automated response system. Resource limitations also inhibit efforts to reduce the reporting interval (and thus increase the timeliness of data), as do technological and regulatory hurdles. The Oklahoma PDMP real-­time reporting project provides a case study on how these can be overcome; see PDMP COE, NFF 3.1 and Data  collection  and  data  quality,  B.  Reduce data collection interval;  move toward real-time data collection, above.

6 - The median reporting interval for states is weekly, according to the Alliance of States with Prescription Monitoring Programs state profiles report, available at


Rationale: Improving timeliness and accessibility of PDMP data may increase utilization and PDMP impact.

Evidence of effectiveness: Case study, unpublished PDMP data on utilization.

Current adoption status: Many states have implemented continuous online access; some have shortened data collection intervals.

Barriers to adoption: Lack of resources to implement online systems and reduce data collection interval.

3. Conduct user education

Rationale and evidence for effectiveness: A good understanding of PDMPs, how to use them, and the value of their data for prescribers, pharmacists, and other end users would likely encourage enrollment in and effective utilization of PDMPs. In its recent funding announcement under the Harold Rogers Grant Program, BJA gave priority consideration to PDMPs proposing to conduct education and outreach to enrolled and prospective PDMP users. States have experimented with various educational formats, including in-­person presentations to prospective user groups, online short courses and Webinars (LeMire, 2010), and paper-­based and Web page materials, such as prescriber "toolkits" on how to use PDMP data and links to Screening, Brief Intervention, and Referral to Treatment (SBIRT) resources. Two published studies suggest that provider education can influence their prescribing behavior (Cochella et al., 2011; Fisher, 2011), but comparative studies of current approaches to prescriber education, their impact on PDMP utilization, and outcomes of such utilization would help identify best practices in this domain. (add www. in footnote below for style consistency; see
early pages).

Education initiatives targeted to law enforcement agencies on the value and use of PDMPs are also needed to help encourage increased utilization in diversion investigations. Current efforts by states and national organizations to educate the law enforcement community about PDMPs need to be identified, cataloged, and evaluated. Other end-­user groups, such as substance abuse treatment clinicians, medical examiners, drug court professionals, and prevention workers, are also candidates for education on PDMPs. To determine best practices in education on PDMPs, field research and evaluations are needed to ascertain what educational programs exist, their costs, and their impact in assisting end users to address prescription drug abuse and diversion. Research and evaluation on education initiatives could be conducted using data from the Prescription Behavior Surveillance System under development by the PDMP COE with funding from BJA, U.S. Food and Drug Administration (FDA), and CDC.

Since many prescribers have insufficient training in the use of opioids and other prescription controlled substances, proposals for mandatory prescriber education have been discussed in the Office of National Drug Control Policy national action plan to address the prescription drug abuse epidemic (Office of National Drug Control Policy, 2011) and in the context of developing national Risk Evaluation and Mitigation Strategies (REMS). Such education could include training in not only the proper use of these drugs but also their misuse and abuse by bona fide patients; the nature and extent of doctor shopping; the extent of theft, counterfeiting, and forgery of prescriptions (Boeuf et al., 2007); and how to access and use PDMP data. States' experience in provider education, for example in Massachusetts, which requires prescriber education on controlled substance prescribing, can serve as guides to educational mandates. The extent to which mandates are feasible and what sorts of education actually change prescriber behavior, including integrating use of PDMPs into clinical practice, are open questions in need of study (Tufts Health Care Institute Program on Opioid Risk Management, 2011).

Current adoption status: To date, only a limited number of educational programs specifically on PDMPs have been developed for prescribers, for example by Connecticut, North Dakota, South Carolina, and Utah (presentations at the 2010 National PDMP Meeting in Washington, D.C.). These could be evaluated to shed light on their comparative effectiveness in terms of changing prescriber behavior and clinical outcomes. Kentucky, Louisiana, Massachusetts, and Montana statutes require education of certain users as a condition of being given access to PDMP data (NAMSDL, 2012c).

Barriers to adoption: PDMPs usually have limited budgets that necessarily restrict the scope of their educational efforts. In addition, little evidence exists on what approaches to prescriber education, and the education of other potential users of PDMPs, actually work to induce greater use of PDMPs. Without such information, states may be reluctant to pursue educational initiatives.


Rationale: Education of prescribers and other potential end users may encourage awareness and effective use of PDMP data.

Evidence of effectiveness: Published studies.

Current adoption status: Some states have fielded seminars, tutorials, Webinars, and other presentations on the value and uses of PDMP data.

Barriers to adoption: Lack of resources and lack of evidence on which educational approaches produce the greatest changes in prescriber and other end-­user behavior.

4. Mandate utilization  

Rationale and evidence of effectiveness: Mandating that providers make use of a PDMP, like mandating enrollment (see B.  Outreach  and  recruitment  strategies,  4.  Mandate  enrollment, above), may be more efficient and cost-­effective in increasing PDMP utilization than encouraging optional participation. The recent move to mandate utilization by some states suggests that some PDMP stakeholders believe that requiring use of the PDMP will work better than voluntary approaches to increasing utilization. However, no research yet exists to support this claim. Because mandates are now being adopted by some states, their efficacy in increasing PDMP use needs study, as do the mechanisms for encouraging and monitoring prescriber compliance and the impact of a mandate on prescribing, patient outcomes, doctor shopping, overdoses, and drug-­related deaths. Incentives for compliance need investigation; for example, PDMP stakeholders and regulatory bodies could consider, with public and private third-­party payers, making the review of PDMP data when
prescribing controlled substances a condition of payment. As in mandating enrollment in a PDMP, mandating utilization may have unintended consequences that experience in states with mandates might bring to light.

Current adoption status: A small but growing number of states statutorily require or recommend that prescribers, pharmacists, and/or addiction treatment providers consult their PDMPs, sometimes only in specific circumstances (NAMSDL, 2012b). In Nevada, statute NRS 639.23507 states that prescribers "shall" obtain a PDMP report when first prescribing a controlled substance for a new patient who they suspect might be doctor shopping, and for patients for whom they have not prescribed controlled substances in the last year. In Oklahoma, prescribers must consult the PDMP when prescribing methadone for treating pain. Recently passed legislation in Ohio requires its medical and pharmacy licensing boards to adopt rules mandating use of its PDMP, which they have done (Ohio Administrative Code Sections 4731-­11-11 and 4729-5-20). In Louisiana, medical directors of pain clinics are now responsible for joining and querying the PDMP to help ensure compliance with a patient's treatment agreement. West Virginia requires that opioid addiction treatment programs access the PDMP when beginning treatment and at 90-­day intervals, and Vermont requires use of its PDMP data by physicians who treat patients for opioid dependence with buprenorphine (Office Based
Opioid Treatment, or OBOT). Kentucky, Massachusetts, New York, and Tennessee have passed laws in 2012 requiring use of the PDMP by prescribers (NAMSDL, 2012b, communication with Massachusetts PDMP).

Barriers to adoption: Monitoring required prescriber use of its system by a PDMP requires staff time and resources that may be unavailable to some PDMPs, presenting a barrier to assuring that prescribers adopt this practice. Other potential barriers include resistance to mandates by providers and enactment of the required legislative or regulatory changes. However, should findings from existing initiatives prove positive, other states could be encouraged to undertake the
necessary legislative and regulatory changes to mandate utilization, and make resources available to implement utilization requirements.

See Section  V.  Summary  and  Recommendations for a recommendation to study the efficacy of mandates in comparison to voluntary approaches with regards to increasing PDMP utilization.


Rationale: Mandating utilization may improve prescribing, patient safety, drug treatment, and licensing board monitoring.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: Several states mandate utilization by different categories of end users under varying circumstances.

Barriers to adoption: Provider resistance to mandates, need for legislative and/or regulatory reform, lack of program resources to monitor compliance.

5. Institute financial incentives

Rationale and evidence for effectiveness: Greater utilization of the PDMP by prescribers could perhaps be encouraged by financial incentives, but little data exist on such approaches. One suggestion is to make lower medical malpractice insurance premiums contingent on regular use of PDMP data. There is a need for studies examining whether prescriber use of PDMP data reduces the number of patient-­initiated lawsuits stemming from alleged mis-prescribing of controlled
substances; such findings could help establish the rationale for charging PDMP-­using prescribers lower insurance premiums. Similarly, health insurance carriers providing somewhat higher office visit fees to prescribers who consult
the PDMP through pay for performance initiatives might also incentivize greater use. Investigation is needed to determine whether any states or agencies have implemented financial incentives to encourage PDMP use, and if they have, what impact they may have had on utilization, prescribing practices, doctor shopping, and other forms of drug diversion.

Current adoption status: As of this writing, we know of no examples of financial incentive programs designed to elicit greater PDMP utilization.

Barriers to adoption: No precedent exists for adopting this practice, so pilot programs should be considered.


Rationale: Financial incentives may increase PDMP utilization.

Evidence of effectiveness: Key stakeholder perceptions.

Current adoption status: None.

Barriers to adoption: Lack of evidence for effectiveness, lack of precedents.

6. Delegate  access  

Rationale and evidence for effectiveness: Allowing prescribers to delegate access to PDMP records by office staff (sometimes called “sub-­‐accounts”), may help increase utilization of PDMP data to detect patients at risk and improve prescribing. However, the extent to which delegate accounts increase PDMP utilization is unknown.

Current adoption status: Twelve states permit prescribers to delegate access to PDMP records (NAMSDL, 2011b), and statutes adopted in 2012 in Kentucky, New York, and Tennessee authorize use of delegates. Some PDMPs permit prescribers to delegate only licensed health care professionals, e.g., nurses, while others allow non-­licensed administrative staff to be delegated. New York’s new statute requires the delegates to be employees of the same practice as the prescriber. Methods to allow prescribers to establish sub-­‐accounts for delegates and to oversee and supervise their data acquisition, as well as methods to hold prescribers accountable for their delegates’ activities, are not standardized. The specific policies and procedures governing delegates, their relative security, and the extent to which they increase the legitimate use of PDMP data in a practice need study. A first step would be to survey states’ current policies, followed by a comparative analysis of their impact on utilization.

Barriers to adoption: Increasing staff access to PDMP data has raised concerns about maintaining patient privacy and confidentiality. Those concerns must be addressed by each state in order for delegate accounts to gain acceptance. Master account holders may find monitoring of sub-accounts for which they are responsible burdensome.


Rationale: Delegating access may increase PDMP utilization.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: Twelve states allow delegated access.

Barriers to adoption: Concerns about data security and patient confidentiality, the need to monitor delegate account users by master account holders. 

Interorganizational best practices for PDMPs

PDMP interorganizational best practices will permit data sharing across PDMPs and integrate PDMP data into the health care system, drug abuse prevention efforts, and the work of investigative agencies. They will enable efficient collaboration among PDMPs and outside organizations engaged in improving patient health and mitigating prescription drug abuse. They will also enable linking PDMP data with other prescription and health data to permit combined analyses and facilitate data access.

Candidate practices include actions to:

A. Enact and implement interstate data sharing among PDMPs 

  1. Model memoranda of understanding (MOUs)
  2. Standardize data collection fields, formats, and transmissions standards
  3. Identify individuals in multistate data
  4. Standardize measures for identifying questionable activity 
  5. Data encryption and de-­identification

B. Collaborate with other health agencies/organizations in applying and linking PDMP data

    1. Department of Veterans Affairs 
    2. Indian Health Service 
    3. Department of Defense
    4. Centers for Medicare and Medicaid Services
    5. Private third-­party payers

A.  Enact and implement interstate data sharing among PDMPs

Rationale: Since doctor shopping and other forms of prescription drug diversion often cross state lines, PDMP data from a single state are limited in their capacity to identify individuals potentially in need of intervention, whether by prescribers or investigative agencies. For example, a review of data in the Kentucky PDMP identified that the prescriptions dispensed by Kentucky pharmacies were issued by prescribers located in all 50 states, the District of Columbia and Puerto Rico; 93.2 percent were issued by Kentucky prescribers, and an additional 5.7 percent were issued
by prescribers in adjoining states. Examination of Massachusetts PDMP data found similar patterns.

Combining data from neighboring states and states known to be major sources of diverted prescription drugs will help increase the capacity to identify diversion and doctor shopping for all participating states. The same advantages accrue in the discovery and investigation of pill mills and aberrant prescribing. The Alliance of States with Prescription Monitoring Programs' PMP Model Act 2010 Revision recommends that exchange of PDMP information be permitted among states (ASPMP, 2010). Under its Harold Rogers Grant Program, BJA has given priority consideration to PDMPs
proposing to implement interstate data sharing.

Current adoption status and evidence of effectiveness: As of 2011, 28 states have provided for data sharing between PDMPs under a variety of statutory and regulatory protocols, including the Prescription Monitoring Information Xchange (PMIX) architecture and the Rx Check Hub, the PMPi Hub, and the Health Information Design (HID) Hub for data sharing (NAMSDL, 2011a). Live data are now being exchanged between Kentucky and Alabama, and between Indiana, Ohio, and several other states to help identify cross-­border doctor shopping and diversion. These states, and others soon to
follow, are in effect pilot testing the various protocols, and so can help identify best practices in all aspects
of data sharing. These include:

1.  Model memoranda of understanding (MOUs)

States need MOUs with their partners to ensure that data are shared fairly, securely, and in compliance with the regulations of all participating states. Existing MOUs, including master templates developed for PMIX and PMPi, can be evaluated as possible models for states considering data-sharing agreements.

2.  Standardize data collection fields, formats, and transmissions standards  

States sharing their data need a minimum set of common data fields, encoded and transmitted in a shared format, such as ASAP 4.2. Different standards for these parameters may exist in current data-sharing projects, which presents the opportunity for comparison using criteria of completeness, reliability, functionality, and ease of adoption. Common data protocols also need to be developed to permit the matching and integration of PDMP data with prescription information
being collected by non-PDMP organizations such as the VA, Medicaid, and third-party payers. See Data collection and data quality, above, for more on data collection standards; the recommendations made there can be extended to multistate standards and initiatives.  

3.  Identify individuals in multistate data

The usefulness of PDMP data depends greatly on the reliable identification of particular individuals who might be engaging in questionable activity. Research is needed on the best methods for identifying and linking the records of specific individuals in multistate PDMP data. Current practices among states can be assessed in comparison to what, according to evidence and expert opinion, is considered the state of the art in identifying individuals in data sets like those of PDMPs. Work on developing best practices for linking data within individual PDMPs (see Data
linking and analysis,  A.  Link  records  to  permit  reliable  identification  of  individuals, above) should be extended to cooperative development of multistate data-linking capabilities.

4.  Standardize measures for identifying questionable activity

States sharing data with one another or non-PDMP agencies may wish to collaborate on developing reliable measures of questionable activity, such as doctor shopping, that apply across state lines or that are appropriate to certain populations. Current efforts to test such measures, should any exist, need to be identified and evaluated with respect to the current literature (e.g., Buurma, 2008; White, 2009; Katz, 2010) and other published studies relevant to this question (see Data
 linking  and  analysis,  B.  Determine  valid  criteria  for  possible  questionable  activity, above).

5.  Data encryption and de-­identification

To conduct analyses of PDMP data for epidemiological, surveillance, and evaluation purposes, records must be de-identified to suppress patient-level information, while maintaining linked individual records in a data set. Methods of encryption appropriate for use by states need to be identified and tested. Currently, a workgroup of the Integrated Justice Information Systems (IJIS) institute is reviewing the methodologies available for linking of patient records within PDMP
databases and anonymization of the data. These would enable de-identified PDMP data from multiple states to be utilized by a surveillance system (e.g., the Prescription Behavior Surveillance System mentioned in PDMP recruitment,
utilization, and education, above) to track doctor shopping, pill mill prescriptions, and other diversion of prescription drugs across state lines. While the workgroup’s review is not yet complete, its findings suggest that less expensive and publicly available systems for linking are not as effective as some proprietary "gold standard" products. PDMPs may need additional resources to enable optimum data encryption, while maintaining accurately linkedindividual records.

Barriers to adoption: Interstate data-sharing agreements involve legal, regulatory, and policy changes requiring coordination between multiple stakeholders, putting demands on scarce PDMP resources. Some states do not yet have statutory or regulatory authority to share data. Some PDMPs have yet to complete the implementation of PDMP operations or other significant enhancements necessary for initiating interstate exchange of data. In addition, many data-­sharing initiatives have not completed standardization to the PMIX architecture that will make sharing among all states


Rationale: Practices that enable cross-­‐state and interorganizational data sharing will increase the application and utility of PDMP data.

Evidence of effectiveness: Expert opinion.

Current adoption status: A few states are currently sharing data; MOUs, data standards, methods of identifying individuals, and encrypting data vary across states and data-­sharing initiatives.

Barriers to adoption: Need to complete PDMP implementation and enhancements in some states, completing standardization of exchange hubs to PMIX architecture, and states’ statutory, regulatory, and resource limitations.

B.  Collaborate with other health agencies/organizations  in applying and linking PDMP data

Rationale: PDMP collaboration with health agencies, such as by matching PDMP data with other medical information, promises to improve patient protection, safety, and health, and increase health data accuracy and interagency communication. It will also increase the visibility and penetration of PDMPs in multiple health contexts, while fostering development of best practices in data integration across systems. Recent experience in Washington State involving the batch transfer of PDMP data on Medicaid patients (see User  access  and  report  dissemination,  B.  Optimize reporting  to  fit  user  needs, above) strongly suggests that collaboration with public health agencies will be effective in helping to improve controlled substance prescribing, and mitigate prescription drug abuse and diversion. Below we describe the status of some current and prospective initiatives that suggest the importance of integrating major health systems with PDMPs to maximize the value of prescription data.

Current adoption status and evidence of effectiveness:    

1.  Department of Veterans Affairs

The VA was granted statutory authority to share its prescription data with state PDMPs in the Budget Reconciliation Act of 2011. The sharing can begin only after the VA completes regulations authorizing it. Regulations, systems, and protocols to support VA-­PDMP data sharing could be documented and evaluated as models for other interorganizational collaborations in addressing prescription drug abuse and diversion. Cooperative work with the VA may also open up new and important avenues for research that could lead to improved medical care and patient safety. For example, if PDMP data can be matched to medical care treatment in VA records, a more thorough understanding of the progression of proper opioid prescribing could be gained, as well as a better understanding of iatrogenic opioid addiction.

2.    Indian Health Service

The IHS is working with BJA, IJIS Institute, the PDMP Training and Technical Assistance Center, and the PDMP COE to share its pharmacies’ data with state PDMPs. The effort includes development of software enabling IHS pharmacies to put their data into the formats each state requires for pharmacy data collection and subsequent transfer of data to each PDMP. Efforts will be undertaken to establish PDMP accounts for IHS prescribers and pharmacists so they can access PDMP data for their patients, with accompanying training in use of PDMP data. In addition, new methodologies need to be developed and authorized for IHS professional supervisors to obtain and review PDMP data as they pertain to the practices of prescribers and dispensers within the IHS system. The IHS system includes quality assurance practices in which professional supervisors oversee the work of prescribers and dispensers. PDMPs have not previously provided data to health care systems’ quality control mechanisms, with the exception of North Dakota and South Dakota, which authorize peer review committees to access data.

Study of the IHS data-­sharing initiative will assist PDMPs in their efforts to link with other health care systems, including the VA, DoD, and CMS. This is particularly important because VA pharmacies use the same pharmacy software system as IHS pharmacies. Successful implementation of IHS pharmacy systems for sharing data with state PDMPs will therefore expedite the VA’s ability to send data to state PDMPs when their regulations are completed.

3.    Department of Defense

The DoD health care system is discussing the possibility of linking its pharmacy data with PDMPs and making state PDMP data available to its prescribers and pharmacists. Given reports on the extent of controlled substances abuse and misuse among military personnel and their families, this effort is important and should be brought to fruition. Linkage is needed with the DoD health care system (for active duty personnel) and Tricare (for dependents and retired military personnel). Legislation authorizing sharing of data between DoD facilities and PDMPs may be required as a
prerequisite to sharing.

4.    Centers for Medicare and Medicaid Services

Sixteen states have made PDMP data available to their state Medicaid agencies and/or fraud investigation units, and the GAO has recommended increasing use of PDMPs by Medicaid agencies and Medicare. The Alliance of States with Prescription Monitoring Programs’ PMP Model Act 2010 Revision also recommends providing PDMP data to Medicaid agencies and Medicare (ASPMP, 2010). However, there is no linkage of PDMPs with the Medicare program, and, as yet, very limited national level policy dialogue with the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS) regarding the coordination of PDMPs with the Medicaid and Medicare programs. Such a dialogue is important because multiple potential best practices could be considered, including:

  • Documenting how state Medicaid agencies have used the PDMP data they have received, and how that
    may have impacted the quality and cost of care for Medicaid recipients.
  • Developing recommended audit procedures for state Medicaid agencies and Medicare organizations to
    use with PDMP data to identify and monitor persons who should be locked in to single prescribers
    and pharmacies, i.e., placed in restricted recipient programs.
  • Developing Medicaid and Medicare policy on encouraging or mandating prescribers to obtain PDMP
    data prior to issuing the first controlled substance prescription to a patient and periodically
  • Developing procedures for Medicare program reviewers or auditors to access and utilize PDMP
    data and developing model state legislation to authorize such access.

5.  Private third-party payers 

The Coalition Against Prescription Fraud has identified that private insurance payers expend in excess of $24.9 billion annually for enrollees who abuse opioid prescriptions (Coalition Against Insurance Fraud, 2007). Workers’ compensation programs that pay claimants’ costs for treatment and rehabilitation following work-related accidents have found opioid misuse to be a significant problem. A recent WorkCompCentral news release stated, "The use of opioids in the nation’s workers’ compensation systems remains a top concern of major insurers, state regulators, and third-party
administrators, according to a survey conducted by the president of a consortium of pharmacy benefit managers" (WorkCompCentral, 2012). The National Council on Compensation Insurance found that a single opioid product had become the highest-­‐costing pharmaceutical for workers’ compensation programs (Lipton, 2011).    

One study suggests that PDMPs are associated with lower claim rates for opioid analgesics at the county level (Curtis et al., 2006), but additional research on the role PDMPs can play in reducing costs is needed. Insurers with policies limiting patients to one prescriber and pharmacy (lock-­ins) could suggest or require that prescribers consult PDMP data to confirm patient compliance. The PDMP COE is planning to follow the Office of National Drug Control Policy’s call for the PDMP COE to convene meeting with PDMPs and third-­party payers in order to open dialogue regarding how they may coordinate activities and work together to interdict the national prescription drug abuse epidemic (CONDCP, 2011). A major topic to be explored is the potential sharing of PDMP data with all third-­‐party payers.

Barriers to adoption: Developing collaborative data-­sharing agreements and the requisite information- sharing protocols with the agencies mentioned above will involve regulatory and policy changes at the state and national levels involving multiple stakeholders. This will require sustained commitment from leaders in the PDMP community and their counterparts within each agency to ensure the allocation of adequate attention and resources.


Rationale: Coordination of PDMPs with wider health systems will enable enhanced use of PDMP data to improve prescribing and patient health and, as a byproduct, to reduce excess public and private costs.

Evidence of effectiveness: Expert opinion (ASPMP Model Act), accumulated experience.

Current adoption status: Data sharing between IHS facilities and PDMPs is under way and between Medicaid programs and PDMPs; the VA is working on regulations to implement such sharing, and the PDMP COE is planning an initial meeting with third-­party payers.

Barriers to adoption: Regulatory and organizational.

Evaluation of PDMPs

Evaluation practices and use of evaluation findings for quality improvement enable PDMPs to respond to changing demands and conditions, and ensure their systems and policies permit maximum appropriate use of high-quality, timely PDMP data. Candidate practices include actions to:

A. Conduct satisfaction and utilization surveys of end users

B. Conduct audits of PDMP system utilization for appropriateness and extent of use

C. Use PDMP data as outcome measures in evaluating program and policy changes

D. Analyze other outcome data (e.g., overdoses, deaths, hospitalizations, ER visits) to evaluate the PDMP’s impact

A survey of PDMP administrators conducted in 2006 found that two states out of 18 responding (and 23 PDMPs active at the time) had completed or were conducting evaluations of the public health impact of PDMP implementation (Katz et al., 2008). Currently, three states have worked with researchers to produce evaluation reports of their PDMP: Kentucky (Blumenschein et al., 2010), Maine (Lambert, 2007), and Virginia (Virginia Department of Health Professions, 2004). At least six others have contracted with researchers to conduct evaluations (Kansas, Massachusetts, North Carolina, North
Dakota, Oregon, and Washington), and other states are in discussions with researchers regarding evaluations and other work (e.g., Florida and Texas). This increase appears to reflect a growing interest by PDMP administrators in addressing end-­user needs (e.g., timely and accurate provision of data to prescribers, pharmacists, law enforcement agencies, regulatory agencies, and others) and in demonstrating program utilization and impact, to assure state legislators that the PDMP is a good investment in an environment of scarce resources.

A.  Conduct satisfaction and utilization surveys of end users 

Rationale: Satisfaction and utilization surveys of PDMP users can provide important feedback for purposes of program enhancement and increasing user buy-­in. Such surveys can be conducted online, by mail, or by phone, and give PDMP administrators insight into aspects of their system that are working well, areas for improvement, and barriers to greater use of the PDMP. Surveys can help build support of the PDMP by end users, who can be important allies in passing legislative changes desired by the PDMP and in securing stable funding.

Current adoption status and evidence of effectiveness: Kentucky, Maine, Massachusetts, and Virginia have reported findings from satisfaction and utilization surveys of end users of their PDMPs (e.g., Rosenblatt, 2007; Sorg et al., 2009; and survey reports linked at the Kentucky PDMP website). Survey feedback from law enforcement and regulatory agencies led Massachusetts to develop an online PDMP portal for their use in active investigations. Accentra Health, in partnership with the Oregon Health Sciences University and the Oregon PDMP, is conducting a survey of prescribers to learn how they use PDMP data in clinical decision making and how these data affect their prescribing practices.

Barriers to adoption: Barriers to conducting surveys include lack of staff time and expertise to design and field surveys, and to analyze and report out data. However, states can look to other PDMPs to assist in developing survey instruments (e.g., by modifying existing instruments), and methods for data collection and analysis.

B.   Conduct audits of PDMP system utilization for appropriateness and extent of use

Rationale: As discussed earlier, a PDMP’s usefulness is maximized if the most active prescribers make frequent use of the PDMP. PDMP utilization audits can show how often these prescribers query the database and download reports. Audits can also be conducted to gauge the impact of viewing prescription history data on prescribing practices. For example, an audit might examine a prescriber’s prescriptions for a patient following a query of the PDMP on that patient, to determine whether any of the controlled substance indicators found to be associated with risk for abuse or overdose were present. An alternative audit might compare a prescriber’s prescriptions for a patient prior to and following one or more queries of the PDMP about that patient. Such audits could be conducted for multiple prescribers and patients, if longitudinal data exists. Audits can also track PDMP utilization by level of prescribing, medical specialty (if this information is made available to the PDMP), and the level of suspected questionable activity within a practice. As
mandates for PDMP utilization are adopted, audits will become increasingly relevant for determining prescriber and dispenser compliance.

Current adoption status and evidence of effectiveness: To our knowledge, no states are systematically auditing PDMP utilization data to evaluate appropriateness of use. However, some states are taking steps prior to such evaluation. Utah, upon determining that many of the most frequent 25 percent of prescribers were not registered with the PDMP, contacted these prescribers to remind them that Utah’s law requires that they register with the program. Within one day, more
than 100 of these prescribers registered with the PDMP (presentation at West Regional PDMP meeting, 2010). Massachusetts is also contacting prescribers with high proportions of possible doctor shoppers in their practices,
recommending that they enroll in and use the PDMP (communication with Massachusetts PDMP). Utilization data of these prescribers could be analyzed to monitor how often they query the PDMP. We expect that states instituting mandates for utilization (e.g., Kentucky, Massachusetts, New York, and Tennessee) will begin regular audits of prescriber queries to their PDMPs.

Barriers to adoption: The primary barrier to auditing PDMP utilization is the staff time required to extract and examine data. States that adopt mandates for use will of necessity have to shift resources to conducting compliance audits. This may reduce resources for other activities unless additional funds and staff are made available.

C.    Use PDMP data as outcome measures in evaluating program and policy changes

Rationale: While PDMPs can have an impact on prescription drug overdoses and other health outcomes, many other factors not under the control of the PDMP can affect such outcomes. A more proximate outcome for PDMP activities is the number of patients possibly engaged in abuse or diversion. As discussed previously (see Data  linking  and  analysis,  C.  Conduct  periodic  analyses  of  questionable  activity, above), this outcome can be measured to an extent using PDMP data. Similarly, as valid and reliable indicators of suspected problematic prescribing on the part of individual providers become available using PDMP data, these too could serve as outcome measures to track the impact of efforts to curtail such prescribing.

Current adoption status and evidence of effectiveness: Wyoming has tracked the number of patients meeting a threshold for doctor shopping following the PDMP’s initiation of unsolicited reporting, and found that this number declined markedly over a two-year period, suggesting the effectiveness of unsolicited reporting. A second effect noted by the Wyoming PDMP was an increase in prescriber registration with and use of the PDMP paralleling the distribution of unsolicited reports (NFF 1.1). Nevada’s PDMP noted similar trends in both the number of patients meeting the threshold for doctor shopping and in prescriber registration with the PDMP following its initiation of unsolicited reporting (NFF
2.5). Unpublished data from Oklahoma and North Carolina on trends of doctor shopping rates show similar effects: As use of the PDMP increases, numbers of individuals meeting thresholds for questionable activity as measured by PDMP data decline (communications with Oklahoma and North Carolina PDMPs).

Barriers to adoption: Limited PDMP resources may affect the extent to which data analyses on outcome measures constructed using PDMP data can be designed and carried out, and then integrated with process evaluation data on program activities that might influence these measures, for instance efforts to increase utilization and send unsolicited reports.

D. Analyze other outcome data (e.g., overdoses, deaths, hospitalizations, ER visits) to evaluate the PDMP’s impact

Rationale: As noted, a number of factors can affect health outcomes besides PDMP operations. This fact has complicated studies of the impact of PDMPs across states (e.g., Simeone & Holland, 2006; Paulozzi et al., 2011), to the point where an effect of PDMPs or a PDMP practice (in these cases, unsolicited reporting) is difficult to detect, at best. An alternative approach, planned in several states but not yet implemented, is to examine changes in health outcomes such as overdose rates at the county level within a state, in relation to: (1) the proportion of prescribers in each county who have registered with the PDMP and regularly query it, and (2) specific PDMP practices, such as unsolicited reporting (e.g., the proportion of patients in a county about whom unsolicited reports have been sent, or the proportion of prescribers in a county to whom an unsolicited report has been sent).

It is important to examine changes in health outcomes in relation to these PDMP-­related factors because high rates of such outcomes may well have triggered a response by the PDMP (unsolicited reports) or practitioners (registration with and use of the PDMP). A study would test for decreases in adverse health outcomes, by county, subsequent to the presence of these factors. Sufficient time, perhaps years in some cases, may be needed to measure these impacts as persons experiencing overdoses have frequently been abusing prescription drugs for multiple years. An effective intervention may
prospectively reduce the numbers of new persons from meeting DMS IV criteria for dependence on or abuse of prescription opioids or other controlled substances, but may be less protective for those already meeting those

Current adoption status and evidence of effectiveness: Although a number of states have recognized the value of evaluating PDMP activities, to our knowledge no states have completed systematic empirical studies of their effectiveness using health outcome data such as described above. Nor have there been studies of the impact of a PDMP’s evaluations of any sort — that is, of whether PDMPs that are conducting or have conducted evaluations are more effective than those that have not.  However, with respect to PDMP impact on health outcomes, it should be noted that overdose death and prescription monitoring data from Wilkes County in North Carolina gathered by Project Lazarus
( suggest that an increase in use of the North Carolina PDMP by county prescribers may have contributed to a sharp decrease in their controlled substance prescribing to county resident overdose decedents. This in turn may have been a factor in the decline in the yearly number of overdose deaths among county residents from 2008 to 2011 (PDMP COE, NFF 3.2).

Barriers to adoption: The level of effort required to design and field PDMP evaluations using health outcome data is considerable, requiring intensive data collection and analysis over a multiyear period. Most PDMPs will not have the trained evaluators needed to conduct such evaluations, but universities and private research institutions are often willing to form partnerships with PDMPs in such endeavors given the increased interest in PDMP studies, provided that funding can be identified for their work.


Rationale: Evaluation of PDMP activities can inform and improve activities and demonstrate the value of a PDMP.

Evidence of effectiveness: Accumulated experience.

Current adoption status: At least 10 states have evaluated or are evaluating their PDMP using satisfaction surveys and outcome measures constructed from PDMP data; a few are planning health outcome evaluations.

Barriers to adoption: Primarily resources needed to conduct or contract for an evaluation.

Funding PDMPs

Best practices in consistent, long-­term funding will enable a stable platform for PDMPs to operate, implement new technologies as needed, and maintain sufficient staffing levels. Adequate funding facilitates data access for authorized users, implementation of interoperability between PDMPs, and effective analysis of prescription information. Candidate best practices in funding include efforts to: 

A. Secure funding independent of economic downturns, conflicts of interest, public policy changes, and changes in PDMP policies

B. Enact legislation to maintain sufficient funding over time

C. Conduct periodic review of PDMP performance to ensure efficient operations and identify opportunities for improvement

Note: Information discussed in this section comes from a survey of state PDMPs conducted by the PDMP Training and Technical Assistance Center at Brandeis University, interviews with PDMP administrators, and analyses of data reported to BJA by PDMPs receiving funds under the Harold Rogers Prescription Drug Monitoring Program Grant Program.

A.  Secure funding independent of economic downturns, conflicts of interest, public policy changes, and changes in PDMP policies

Rationale: To ensure a viable and effective PDMP in a time of shrinking public revenues, prescription monitoring advocates and stakeholders must take advantage of all available funding opportunities. These fall into four general categories: grants, licensing fees, general revenue, and board funds. Other less common sources of support include settlements, insurance fees, private donations, and asset forfeiture funds.

Current adoption status and evidence for effectiveness: As described below, many PDMPs employ more than one method of securing financial support, each of which has its advantages and disadvantages.

a.    Grants. There are 36 PDMPs that receive funding through some type of grant (federal: 36 PDMPs; industry: 2 PDMPs; state: 1 PDMP). Grant funding can be used to start planning the establishment of a PDMP (BJA Harold Rogers grants), implement a PDMP (Harold Rogers and NASPER7 grants), operate a PDMP (National Association of State Controlled Substances Authorities [NASCSA] grants), enhance a PDMP (Harold Rogers, NASPER, and NASCSA grants), and promote a PDMP through education (NASCSA grants). Currently, there are 18 PDMPs that have grants as their sole funding source; 14 of them passed enabling legislation or have become operational since 2007. The availability of grant funding has facilitated the creation or enhancement of the majority of PDMPs. However, there are problems in relying on grants to fund a PDMP. Funds are limited in amount, often made available only for specific purposes,
subject to periodic renewal, and limited in duration; there is no guarantee that a PDMP will receive a grant award or a renewal.

7 - The NASPER grant program is currently unfunded but has provided support to PDMPs in earlier years.

b.    Licensing fees. There are 15 PDMPs that receive funding through a registrant’s licensing fee. A state may assess a fee for prescribing/dispensing controlled substances or to practice medicine or pharmacy; a portion of the collected fees are used to support the PDMP. There are 14 PDMPs that obtain funding from controlled substance registry license fees, and three that obtain funding from state health license fees. There are currently five PDMPs that have licensing fees as their sole funding source; four became operational
prior to 2007. Although licensing fees provide a steady source of funding, in most cases, the percentage of the licensing fee allocated to the PDMP is small. In order to increase the percentage or amount, legislative action may be required. Some licensees may have objections to supporting a program that they may not use routinely.

c.    General revenue. There are 10 PDMPs that receive funding through dedicated monies from a state’s general revenue fund. There are four PDMPs that have general revenue monies as their sole funding source, all of which became operational prior to 1997. Although funds from a state’s general revenue fund provide a steady source of support, the amount can be influenced by economic and political conditions. In times of economic distress, a state may be forced to reduce budgets or reapportion monies. Programs that increase public and lawmakers’ awareness of PDMP’s contribution to addressing the prescription drug epidemic, and that demonstrate its role in reducing health-related costs, will be most successful in securing general revenues.

d.    Board funds. There are six PDMPs that receive funding from monies allotted to licensing boards, most commonly boards of pharmacy; two have board funds as their sole funding source. Although board funds provide a steady source of support, in most cases the percentage of the funds allocated to the PDMP is small. Additionally, a board has several responsibilities requiring funds, so increasing funds or providing adequate funds for a PDMP may be difficult, if not impossible. Some licensees may disagree about supporting a program that they may or may not use routinely.

e.    Other. This category of funding is less common, but reflects the varied funding options that can be employed:

  • Settlements — Two PDMPs are funded through monies obtained from settlements: one settlement from a
    pharmaceutical company and one from tobacco companies. Settlements can result in a large amount of funds for a PDMP, but they are finite and, typically, the settlement money is deposited into a state’s general revenue fund.
  • Insurance fees — One PDMP is funded through fees on health insurance providers.
    Even though the insurers reap savings by utilizing a PDMP, there may be resentment that the cost of
    the PDMP is borne solely by those with insurance.
  • Private donations — One PDMP has established a direct support organization, a 501(c)(3) corporation, to raise funds for the PDMP. This is a creative way to provide monies for a PDMP, but fundraising efforts must be maintained, could result in conflicts of interest, and do not guarantee consistent funding over time.
  • Asset forfeiture funds — One PDMP receives asset forfeiture funds from sheriffs’ offices and police departments, donated through its direct support organization.

The current funding mechanisms have both positive and negative aspects. Ideally, funding should be obtained from those entities that benefit from the existence of the PDMP, contribute to the prescription drug abuse problem, or profit from the sale of controlled substances.

Those that benefit from PDMPs include prescribers, dispensers, health licensing boards, law enforcement agencies, insurance providers, hospitals, medical examiners, and substance abuse treatment programs (see PDMP  recruitment,  utilization  and  education,  A.  Enable  access  to  PDMP  data  by  all  appropriate  users, above, for others).

  • In many cases, some of these beneficiaries are currently funding PDMPs. As an alternative to a flat fee, fees could be determined by the number of prescriptions or dosage units prescribed and dispensed, number of patients receiving controlled substances, etc.
  • A source for funding PDMPs that could be expanded is monies from contributors to the prescription abuse problem. The diversion of prescription medications is nationwide. Individuals are arrested and convicted for diversion, and law enforcement agencies are seizing assets obtained from the illegal proceeds. Law enforcement agencies could contribute such funds voluntarily (see "Asset  forfeiture funds" above) or a "PDMP fine" could be assessed by a court, which could provide some funding for a PDMP. If a PDMP were instrumental in assisting a law enforcement agency in a diversion investigation, it arguably has a legitimate claim to share the assets obtained as a result of the investigation.

The entities that profit from sales of controlled substances — manufacturers  and distributors — are a largely untapped source for funding. Manufacturers could be assessed a fee on the volume of controlled substances produced, and distributors on the number of controlled substances sold.

Barriers to adoption: Barriers to securing funding by the means described above include opposition from those wanting to limit prescription monitoring, lack of PDMP leadership to spearhead funding initiatives, failure to include all stakeholders in advocating for PDMP support, lack of public awareness of the benefits of PDMPs, and lack of resources and expertise to apply for grants or establish nonprofit corporations.

B.     Enact legislation to maintain sufficient funding over time

Rationale: To ensure that a PDMP is adequately funded, states could draft legislation that not only provides monies for effective operation, but also incorporates new technologies and methodologies, as needed. Legislation can specify the source of funds, for what they can be used, and other permissible funding options.

Current adoption status: Below are examples of legislative language on funding, one from the Alliance of States with Prescription Monitoring Programs PMP Model Act and three from Louisiana, Texas, and Florida. Other states’ legislative language (not limited to that concerning funding) is available at the Alliance of States with Prescription Monitoring Programs’ website (­ laws-­and-rules).

The Alliance of States with Prescription Monitoring Programs’ PMP Model Act 2010 Revision recommends the funding come from prescribers (ASPMP, 2010). It states, in part:

  • "The [designated state agency] may charge each prescriber an amount sufficient to cover the costs of . . . operating the prescription monitoring program. [Note: States may choose to use an alternative method . . . to pay the cost of their . . . monitoring system, for example, through controlled substances registration fees.]"

Louisiana’s PDMP statute allows the state’s pharmacy board to obtain grant funding if the legislature does not provide full funding. It states, in part:

  • "The Board shall have the authority to make application for, receive, and administer grant funding from public or private sources for the development, implementation, or enhancement of the prescription monitoring program."
  • "In the event the legislature provides full funding for the prescription monitoring program, no fees shall be levied as provided in this Section."

Texas's statute requires that controlled substance registration fees be used to cover the costs of the PDMP and that the funds can be used only for administration and enforcement of the Controlled Substances Act. The statute also sets a maximum fee amount. It states, in part:

  • "The director may charge a nonrefundable fee of not more than $25 before processing an application for annual registration and may charge a late fee of not more than $50 for each application for renewal the department receives after the date the registration expires. The director by rule shall set the amounts of the fees at the amounts that are necessary to cover the cost of administering and enforcing this subchapter."
  • "The director shall deposit the collected fees to the credit of the operator's and chauffeur's license account in the general revenue fund. The fees may be used only by the department in the administration or enforcement of this subchapter."

Florida’s statute requires that funding come from federal grants or private funding. It establishes a direct-support organization to seek those funds. It states, in part:

  • "All costs incurred by the department in administering the prescription drug monitoring program shall be funded through federal grants or private funding applied for or received by the state. The department may not commit funds for the monitoring program without ensuring funding is available. The department and state government shall cooperate with the direct-support organization ... in seeking federal grant funds, other non-state grant funds, gifts, donations, or other private moneys for the department so long as the costs of doing so are not considered material. Funds provided, directly or indirectly, by prescription drug manufacturers may not be used to implement the program."
  • "The department may establish a direct-­‐support organization that has a board consisting of at least five members to provide assistance, funding, and promotional support for the activities authorized for the prescription drug monitoring program." 

Evidence for effectiveness: To our knowledge, no systematic study relating legislation on funding to actual PDMP support has been conducted. However, it seems likely that language making provisions for PDMP funds tied to specific sources that will remain available, e.g., provider licensing fees, increases the probability of stable funding.

Barriers to adoption: Enacting legislation to provide stable funding for PDMPs requires marshaling majorities in legislative bodies, which in turn requires building popular support for these programs. As noted above, prescription monitoring advocates may face opposition from those wanting to limit the effectiveness of PDMPs, so they must forge alliances with all concerned stakeholders to ensure sufficient support for the legislation by lawmakers and their constituents.

C.  Conduct periodic review of PDMP performance to ensure efficient operations and identify opportunities for improvement

Rationale: A periodic review is beneficial and recommended when a program is funded by monies from public sources or assessed fees. The purposes for the review should be to assess the overall effectiveness of the program, evaluate current performance, evaluate staffing levels, evaluate technological capabilities, and identify areas for improvement. The goals of the review are to ensure the PDMP is operating efficiently and having a positive effect on the health care of
citizens, while reducing the incidence of prescription drug abuse and diversion. It also reinforces the perception (and reality) of program accountability. The review should provide specific recommendations to enhance the PDMP’s effectiveness and adjust funding levels accordingly. The review should be conducted by stakeholders impacted by the PDMP, such as representatives from health care, regulatory, law enforcement agencies, and patient advocacy entities. Reviews can be coordinated with and draw from internal PDMP evaluations (see Evaluation  of  PDMPs, above).

Current adoption status and evidence of effectiveness: As noted above, a few states have conducted or are in the process of conducting evaluations of their PDMPs. To date, there has been no systematic study of how such evaluations may have influenced funding decisions on the part of legislatures or other funding sources. However, since findings from PDMP satisfaction surveys of PDMP users (primarily prescribers) in states such as Kentucky and Ohio have been very positive, they have likely played a role in motivating continued funding for PDMPs in these states.

Barriers to adoption: PDMPs may not have the resources or expertise to carry out comprehensive program reviews.


Rationale: Stable and adequate funding of PDMPs is essential for consistent operation and optimum utilization.

Evidence of effectiveness: Accumulated experience, key stakeholder perceptions.

Current adoption status: States differ widely in their approaches to funding PDMPs.

Barriers to adoption: Barriers include state revenue shortfalls, difficulties in negotiating legislative and regulatory changes, and the need to build sufficient constituent support to motivate stable funding. 

Date added:
Sep 19, 2012
Drug Safety
Collapse All


Alliance of States with Prescription Monitoring Programs (ASPMP). (2007). An assessment of state prescription monitoring program effectiveness and results. Retrieved Sep. 11, 2012, from

Alliance of States with Prescription Monitoring Programs (ASPMP). (2010). Prescription Monitoring Program Model Act 2010 revision.  Retrieved Feb. 26, 2012, from

Baehren, D.F., Marco, C.A., Droz, D.E., Sinha, S., Callan, E.M., & Akpunonu P. (2010). A statewide prescription monitoring program affects emergency department prescribing behaviors. Annals of Emergency Medicine, 56(1), 19-­‐23.

Barrett, K., & Watson, A. (2005). Physician perspectives on a pilot prescription monitoring program. Journal of Pain and Palliative Care Pharmacotherapy, 19(3), 5-­‐13. 

Blumenschein, K., Fink, J.L., Freeman, P.R., Kirsh, K.L., Steinke, D.T., & Talbert, J. (2010). Independent evaluation of the impact and effectiveness of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER). Lexington, Kentucky: Institute for Pharmaceutical Outcomes and Policy, University of Kentucky. Retrieved Sep. 11, 2012, from­B1A1-­4399-89AD-­25953BAD43/0/KASPEREvaluationFinalReport10152010.pdf

Boeuf, O., & Lapeyre-Mestre, M. (2007). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: Results of OSIAP survey. Drug Safety, 30(3), 265-­‐276. 

Bohnert, A.S., Valenstein, M., Bair, M.J., Ganoczy, D., McCarthy, J.F., Ilgen, M.A., & Blow, F.C. (2011). Association between opioid prescribing patterns and opioid overdose-­related deaths. Journal of the American Medical Association, 305(13), 1315-­‐1321. 

Buurma, H., Bouvy, M.L., De Smet, P.A., Floor-­‐Schreudering, A., Leufkens, H.G., & Egberts, A.C. (2008). Prevalence and determinants of pharmacy shopping behaviour.  Journal of Clinical Pharmacy and Therapeutics, 33, 17–23.

Campbell, K.M., Deck, D., & Krupski, A. (2008). Record linkage software in the public domain: a comparison of Link Plus, The Link King, and a ‘basic’ deterministic algorithm. Health Informatics Journal, 14(1), 5-­‐15.

Carnevale & Associates and Prescription Drug Monitoring Program Center of Excellence. (2010). Prescription monitoring and prevention: recommendations for increased collaboration. Working paper produced for the Substance Abuse and Mental Health Services Administration. 

Centers for Disease Control and Prevention. (2010). Unintentional drug poisoning in the United States. Retrieved Feb. 26, 2012, from­issue-­brief.pdf

Coalition Against Insurance Fraud. (2007). Prescription for peril: how insurance fraud finances theft and abuse of addictive prescription drugs. Retrieved Sep. 11, 2012, from

Cochella, S., & Bateman, K. (2011). Provider detailing: an intervention to decrease prescription opioid deaths in Utah. Pain Medicine, 12(Suppl 2), S73-­‐S76. doi: 10.1111/j.1526-­‐4637.2011.01125.x.

Curtis, L.H., Stoddard, J., Radeva, J.I., Hutchison, S., Dans, P.E., Wright, A., Woosley, R.L., & Schulman, K.A. (2006). Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Services Research, 41(3 Pt 1), 837-­‐855.

DuBose P., Bender A., & Markman, J.W. (2011, June). Rank-­‐ordering physicians by opioid abuse and diversion risk. Poster presented at the International Narcotics Research Conference, Hollywood, FL.

Dunn, K.M.,  Saunders, K.W., Rutter, C.M., Banta-­‐Green, C.J., Merrill, J.O., Sullivan, M.D., Weisner, C.M., Silverberg, M.J., Campbell, C.I., Psaty, B.M., & Von Korff, M. (2010). Opioid prescriptions for chronic pain and overdose. Annals of Internal Medicine, 152(2), 85-­‐93.

Eadie, J.L. (1990). Policy concerns: benzodiazepine abuse and misuse: New York State’s response. In B.B. Wilford (Ed.), Balancing the Response to Prescription Drug Abuse: Report of a National Symposium on Medicine and Public Policy (pp. 93-­‐102). Chicago IL: American Medical Association.

Eadie, J.L. (1993). New York State triplicate prescription program. In J.R. Cooper, D.J. Czechowicz, S.P. Molinari, & R.C. Petersen (Eds.), Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care: NIDA Research Monograph 131 (pp. 176-­‐193). Rockville, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse.

Eadie, J.L. (2010, May). Prescription monitoring programs and law enforcement: an overview. Presentation made at the PDMP/Law Enforcement meeting, Alliance of States with Prescription Monitoring Programs, San Antonio, TX.

Eadie, J.L. (2011, March). Prescription monitoring program roles. Presentation made at the Surgeon General’s Expert Panel on Prescription Drug Abuse in Youth, Washington, DC.

Eadie, J.L. (2011, May). Toward the next generation of PMPs: enhancing prescription monitoring programs’ ability to address the prescription drug abuse epidemic. Presentation made to the U.S. Senate Sub-­Committee on Crime and Terrorism, Washington, DC.

Feldman, L., Williams, K.S., Coates, J., & Knox. M. (2011). Awareness and utilization of a prescription monitoring program among physicians. Journal of Pain and Palliative Care Pharmacotherapy, 25(4), 313-­‐317.

Fischer, B., Jones, W., Krahn, M., & Rehm, J. (2011). Differences and over-­‐time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-­2010. Pharmacoepidemiology and Drug Safety, 20(12), 1269-1277. doi: 10.1002/pds.2190.

Fisher, J.E., Zhang, Y., Sketris, I., Johnston, G., & Burge, F. (2011). The effect of an educational intervention on meperidine use in Nova Scotia, Canada: a time series analysis. Pharmacoepidemiology and Drug Safety, 21(2), 177-­‐183. doi: 10.1002/pds.2259.

Fisher, J.E., Sanyal, C., Frail, D., & Sketris, I. (2011). The intended and unintended consequences of benzodiazepine monitoring programmes: a review of the literature. Journal of Clinical Pharmacy and Therapeutics, 37(1), 7-­21. doi: 10.1111/j.1365-­‐2710.2011.01245.x.

Fornili, K., & Simoni-­‐Wastila, L. (2011). Prescription monitoring programs: striking the balance between medical use and diversion. Journal of Addictions Nursing, 22(1-­2), 77-82.

Gilson, A.M., Fishman, S.M., Wilsey, B.L., Casamalhuapa, C., & Baxi, H. (2012). Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes. Journal of Pain, 13(2), 103-111.

Gomes, T., Mamdani, M., Dhalla, I., Paterson, M., & Juurlink, D. (2011). Opioid dose and drug-related mortality in patients with nonmalignant pain. Archives of Internal Medicine, 171(7), 686-­‐691.

Government Accountability Office (GAO). (2011). Medicare Part D: instances of questionable access to prescription drugs. (GAO-­12-104T). Washington, DC. Retrieved Sep. 11, 2012, from

Government Accountability Office (GAO). (2009). Medicaid: fraud and abuse related to controlled substances identified in selected states (GAO-­‐09-­‐957). Washington, DC. Retrieved Sep. 11, 2012, from

Hall, A.J., Logan, J.E., Toblin, R.L., Kaplan, J.A., Kraner, J.C., Bixler, D., Crosby, A.E., & Paulozzi, L.J.
(2008). Patterns of abuse among unintentional pharmaceutical overdose fatalities. The Journal of American Medical Association, 300(22), 2613-­‐20.

Johnson, E.M., Porucznik, C.A., Anderson, J.W., & Rolfs, R.T. (2011). State-­level strategies for reducing prescription drug overdose deaths: Utah's prescription safety program. Pain Medicine, Suppl 2:S66-­‐72. doi: 10.1111/j.1526-­1637.2011.01126.x.

Joranson, D.E. & Dahl, J.L. (1989). Achieving balance in drug policy: the Wisconsin model. In C.S. Hill, Jr. & W.S. Fields, Advances in Pain Research and Therapy (pp. 197-­‐204). New York, NY: Raven Press.

Joranson, D.E., Carrow, G.M., Ryan, K.M., Schaefer, L., Gilson, A.M., Good, P., Eadie, J., Peine, S., & Dahl, J.L. (2002). Pain management and prescription monitoring. The Journal of Pain Symptom Management, 23(3), 231-8.

Katz, N., Houle, B., Fernandez, K.C., Kreiner, P., Thomas, C.P., Kim, M., Carrow, G.M., Audet, A, & Brushwood, D. (2008). Update on prescription monitoring in clinical practice: a survey study of prescription monitoring program administrators. Pain Medicine, 9(5):587-­‐94. Epub 2008 Jun 28.

Katz, N., Panas, L., Kim, M., Audet, A.D., Bilansky, A., Eadie, J., Kreiner, P., Paillard, F.C.,  Thomas, C., & Carrow, G. (2010). Usefulness of prescription monitoring programs for surveillance: analysis of Schedule II opioid prescription data in Massachusetts, 1996-­‐2006. Pharmacoepidemiology and Drug Safety, 19(2), 115-­‐23.

Kentucky Cabinet for Health and Family Services and Kentucky Injury Prevention and Research Center. (2010). 2010 KASPER satisfaction survey: executive summary. Retrieved Sep. 11, 2012, from­‐924B-­4F11-­A10A-­5EB17933FDDB/0/2010KASPERSatisfactionSurveyExecutiveSummary.pdf

Kreiner, P. (2011, June). Non-­‐medical prescription drug use and market intervention: prescription drug monitoring program data and law enforcement. Presentation made at the National Institutes of Justice Annual Conference, Washington, DC.

Kreiner, P. (2012, April). Geospatial analyses of opioid overdose rates and rates of questionable activity in Massachusetts. Presentation made at the National Prescription Drug Abuse Summit, Orlando, FL.

Lambert, D. (2007). Impact evaluation of Maine’s prescription drug monitoring program.  Portland, ME: Muskie School of Public Service, University of Southern Maine.  Retrieved Sep. 11, 2012, from;jsessionid=FAED7067735280

LeMire, S. (2010). Evaluation of the efficacy of the North Dakota prescription drug monitoring program online training. Grand Forks, ND: Bureau of Educational Services and Applied Research (BESAR), University of North Dakota. Retrieved Sep. 11, 1012, from

LeMire, S., Martner, S., & Rising, C. (2012). Advanced practice nurses’ use of prescription drug monitoring program Information. The Journal for Nurse Practitioners, 383-­‐405. doi: 10.1016/j.nurpra.2012.02.016

Lipton, B., Laws, C., & Li, L. (2011). Workers compensation prescription drug study: 2011 update, NCCI Research Brief. Boca Raton, FL: National Council on Compensation Insurance Holdings Inc.
Retrieved Sep. 11, 2012, from

Lohr, K.N. (2004). Rating the strength of scientific evidence: relevance for quality improvement programs.  International Journal of Quality Health Care, 16(1), 9-­18.

Massachusetts Department of Public Health. (2010, August). Request to Public Health Council for final promulgation of amendments to regulations implementing the Controlled Substances Act, 105 CMR 700.000, concerning the Prescription Monitoring Program. Public Health Advisory Council Meeting, Boston, MA.

Massachusetts Department of Public Health. (2012, February). PDMP Advisory Council presentation. Public Health Advisory Council Meeting, Boston, MA.

Massachusetts Department of Public Health. (2012, April). Presentation made at National Rx Drug Abuse Summit, Washington, DC.

McDonald, D., Hurd, D., Lloyd-­‐Kolkin, S., Hamilton, C., Reddy, P., & Adedokun, L. (2004). Prescription monitoring programs: current practices and suggestions for further research on their effectiveness. Cambridge, MA: Abt Associates.

National Alliance for Model State Drug Laws. (2011a). Interstate sharing of prescription monitoring database information. Retrieved June 28, 2012, from

National Alliance for Model State Drug Laws. (2011b). States that allow practitioners to designate an authorized agent to access the PMP database. Retrieved June 28, 2012, from

National Alliance for Model State Drug Laws. (2012a). States that require practitioners to register for PMP database. Retrieved June 28, 2012, from

National Alliance for Model State Drug Laws. (2011b). States that require prescribers and/or dispensers to access PMP database in certain circumstances. Retrieved June 28, 2012, from

National Alliance for Model State Drug Laws. (2012c). States that require certain authorized users to undergo training and/or completion of educational courses before accessing PDMP data. Retrieved Sep. 11, 2012, from

Office of National Drug Control Policy. (2011). Epidemic: responding to America’s prescription drug abuse crisis. Washington, DC:  Executive Office of the President of the United States. Retrieved Feb. 26, 2012, from­‐content/prescription-­

Owens, D.K., Lohr, K.N., Atkins, D., Treadwell, J.R., Reston, J.T., Bass, E.B., Chang, S., & Helfand, M. (2010). AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research and quality and the effective health-­care program. The Journal of Clinical  Epidemiology, 63(5), 513-­‐23.

Paulozzi, L.J., & Stier, D.D. (2010). Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania. The Journal of Public Health Policy, 31(4), 422-­‐32.

Paulozzi, L.J., Kilbourne, E.M., & Desai, H.A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine, 12(5), 747-­‐54. doi: 10.1111/j.1526-­‐4637.2011.01062.x. Epub 2011 Feb 18.

Paulozzi, L.J. (2011, June). High-­‐decile prescribers: all gain, no pain? Presentation made at the 2011 Harold Rogers Prescription Drug Monitoring Program National Meeting, Washington, DC.

Paulozzi, L.J., Kilbourne, E.M., Shah, N.G., Nolte, K.B., Desai, H.A., Landen, M.G., Harvey, W., & Loring, L.D. (2012). A history of being prescribed controlled substances and risk of drug overdose death. Pain Medicine, 13, 87-­‐95.

Pauly, V., Frauger, E., Pradel, V., Rouby, F., Berbis, J., Natali, F., Reggio, P., Coudert, H., Micallef, J., & Thirion, X. (2011). Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse. Drug and Alcohol Dependence, 113(1), 29-­‐36. Epub 2010 Aug 8.

Payne, S., & Thayer, D. (2009). Epidemiological analysis of the Maine prescription monitoring program (PMP) data. Portland, ME: Muskie School of Public Service, University of Southern Maine. Retrieved Sep. 11, 2012, from­‐PMP.pdf

Pearson, S., Soumerai, S., Mah, C., Zhang, F., Simoni-­‐Wastilla, L., Salzman, C., Cosler, L., Fanning, T., Gallagher, P., & Ross-­‐Degnan, D. (2006). Racial disparities in access after regulatory surveillance of benzodiazepines. Archives of Internal Medicine, 166, 572-­‐579.

Peirce, G.L., Smith, M.J., Abate, M.A., & Halverson, J. (2012). Doctor and pharmacy shopping for controlled substances. Medical Care, 50(6), 494-­‐500.

Perrone, J., & Nelson, L. (2012). Medication reconciliation for controlled Substances: an “ideal” prescription drug monitoring program. The New England Journal of Medicine, 10.1056/NEJMp1204493.

Pradel, V., Frauger, E., Thirion, X., Ronfle, E., Lapierre, V., Masut, A., Coudert, C., Blin, O., & Micallef, J. (2009). Impact of a prescription monitoring program on doctor-­‐shopping for high dosage buprenorphine. Pharmacoepidemiology and Drug Safety, 18(1), 36-­‐43.

Prescription Drug Monitoring Program Center of Excellence. (2010). Positive customer identification. Unpublished analysis of state prescription monitoring data.

Prescription Drug Monitoring Program Center of Excellence. (2010). Unpublished analysis of PDMP performance measure data collected by the Bureau of Justice Assistance.

Prescription Drug Monitoring Program Center of Excellence. (2010). Trends in Wyoming PDMP prescription history reporting: evidence for a decrease in doctor shopping? NFF 1.1. Heller School, Brandeis University. Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2011). Unpublished analysis of the Second State PDMP Profiles Survey conducted for the Bureau of Justice Assistance.

Prescription Drug Monitoring Program Center of Excellence. (2011). Staying clear of the law and addiction: Nevada’s Pre-­‐Criminal Intervention Program. NFF 2.1. Heller School, Brandeis University. Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2011). Briefing on PDMP effectiveness: PDMPs—an effective tool in curbing the prescription drug abuse epidemic. Heller School, Brandeis University. Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2011). Keeping patients safe: a case study on using prescription monitoring program data in an outpatient addictions treatment setting. NFF 2.2. Heller School, Brandeis University, Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2001).Perspective from Kentucky: using PDMP data in drug diversion investigations. Notes from the Field 2.3. Heller School, Brandeis University. Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2011). Monitoring and changing behavior: the role of PDMP data in Kentucky drug courts. NFF 2.4. Heller School, Brandeis University. Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2011). Nevada’s proactive PDMP: the impact of unsolicited reports. NFF 2.5. Heller School, Brandeis University. Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2011). Drug-related deaths in Virginia: medical examiner use of PDMP data. NFF 2.6. Heller School, Brandeis University. Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2012). Real-­time reporting: Oklahoma’s pioneering PDMP. NFF 3.1. Heller School, Brandeis University. Waltham, MA.

Prescription Drug Monitoring Program Center of Excellence. (2012). Project Lazarus: using PDMP data to mobilize and measure community drug abuse prevention. NFF 3.2. Heller School, Brandeis University. Waltham, MA.

Reifler, L.M., Droz, D., Bartelson, B.B., Bailey, J.E., Schnoll, S., & Dart, R.C. (2012). Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Medicine 2012:13, 434–442.

Reisman, R.M., Shenoy, P.J., Atherly, A.J., & Flowers, C.R. (2009). Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring efficacy. Substance Abuse: Research and Treatment. 2009:3, 41-­‐51.

Rigg, K.K., March, S.J., & Inciardi, J.A. (2010). Prescription drug abuse and diversion: role of the pain clinic. Journal of Drug Issues. 40(3), 681-­‐702.

Rosenblatt, N. (2007). Reducing the diversion of scheduled prescription medications in the Commonwealth of Kentucky: 2006 KASPER Satisfaction Survey: Executive summary. Kentucky Cabinet for Health and Family Services: Frankfort, KY.

Simeone, R. & Holland, L. (2006). An evaluation of prescription drug monitoring programs. Simeone Associates, Inc. Albany, NY. Retrieved on September 11, 2012 from

Sorg, M., Labrie, S., & Parker, W. (2009). Analysis and evaluation of participation by prescribers and dispensers in the Maine state prescription monitoring program. Margaret Chase Smith Policy Center, University of Maine. Retrieved on September 11, 2012 from

Substance Abuse and Mental Health Services Administration, National All Schedules Prescription Electronic Reporting Act Program Grants. (2005). Request for Applications (RFA) No. TI-­‐11-­‐F1, Catalogue of Federal Domestic Assistance (CFDA) No.: 93.975. p. 10.

Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network. (2010). Highlights of the 2009 Drug Abuse Warning Network (DAWN) findings on drug-­related emergency department visits. The DAWN Report. DAWN10-­‐1228. Retrieved on September 11, 2012, from­of-­the-2009-Drug-Abuse-Warning-­Network-­DAWN-­Findings-on-Drug-­Related-Emergency-­Department-­Visits/DAWN10-1228

Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set. (2011) Substance abuse treatment admissions for abuse of benzodiazepines. The TEDS Report. TEDS11-­0602. Retrieved on September 11, 2012, from­Abuse-­Treatment-Admissions-for-­Abuse-­of-Benzodiazepines/TEDS11-­0602

Tufts Health Care Institute Program on Opioid Risk Management. (2011). Advancing safe opioid prescribing through prescriber training and behavior change. Retrieved on September 11, 2012, from

Twillman, R. (2006). Impact of prescription monitoring programs on prescription patterns and indicators of opioid abuse. Journal of Pain, Supplement. 7(4), S6.

Ulbrich, T.R., Dula, C.A., Green, C.G., Porter, K., & Bennett, M.S. (2010). Factors influencing community pharmacists' enrollment in a state prescription monitoring program. Journal of the American Pharmacists Association. 50(5), 588-­‐94.

United States Government Accountability Office (GAO). (2002). Prescription drugs: state monitoring programs provide useful tool to reduce diversion. Washington, D.C. GAO Report GAO-­‐02-­‐634.

Virginia Department of Health Professions and Virginia State Police. (2004). Prescription monitoring program. Richmond, VA. Retrieved September 11, 2012, from

Virginia Prescription Monitoring Program. (2010). 2010 Statistics. Retrieved September 11, 2012, from

Wang, J., & Christo, P.J. (2009). The influence of prescription monitoring programs on chronic pain management. Pain Physician. 12(3), 507-­‐515.

White, A.G., Birnbaum, H.G., Schiller, M., Tang, J., & Katz, N.P. (2009). Analytic models to identify patients at risk for prescription opioid abuse. American Journal of Managed Care. 15(12), 897-906.

Whitely, M.  (2012, January) Opioids pose major concern for comp stakeholders. Workcompcentral available by subscription at­‐ K71GSo

Wilsey, B.L., Fishman, S.M., Gilson, A.M., Casamalhuapa, C., Baxi., H, Zhang, H., & Li, C.S. (2010). Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics. Drug and Alcohol Dependence. 112(1-­‐2), 99-106. Prescription Drug  Monitoring Programs: An Assessement of the Evidence for  Best Practices

Wilsey, B.L., Fishman, S.M., Gilson, A.M., Casamalhuapa, C., Baxi., H, Lin, T.C., & Li, C.S. (2011). An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Monitoring Program. Pharmacoepidemiology and Drug Safety. 20(12), 1262-8. doi: 10.1002/pds.2129.

Related Resources

Pew Testimony Before the U.S.-China Economic and Security Review Commission

Other Resource

Allan Coukell, senior director of drugs and medical devices, testified before the U.S.-China Economic and Security Review Commission on the global pharmaceutical supply chain security and the importance of the newly passed Drug Quality and Security Act.


Testimony of Elizabeth Jungman on Counterfeit Medicines

Issue Brief

The House Energy and Commerce Subcommittee on Oversight and Investigation held a hearing on Feb 16 entitled "Counterfeit Drugs: Fighting Illegal Supply Chains." Elizabeth Jungman, director of drug safety and innovation testified on counterfeit drugs the importance that newly passed Drug Quality and Security Act will have on the safety of the U.S. pharmaceutical supply chain.



Case Studies: How Unsafe Drugs Can Reach Patients

Issue Brief

The following case studies illustrate breaches to the pharmaceutical supply chain—the route a drug travels from its raw material origins to the delivery of a finished medicine. These examples, all of which are discussed in Pew Health Group’s report After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, demonstrate the different ways in which contaminated, fake, or otherwise unsafe medicine can reach patients, and underscore the need for reform.


Pew Comments to FDA Draft Guidance on 503A

Issue Brief

On January 31, Pew submitted comments to the U.S. Food and Drug Administration in response to draft guidance on the implementation of Title I of the Drug Quality and Security Act and addressed five topics: anticipatory and office stock compounding; quality standards; FDA / state coordination; MOUs to address inordinate interstate shipment of compounded drugs; use of bulk drug substances.


Improving the Safety and Quality of Our Drug Supply

Other Resource
On Nov. 18, 2013, Congress passed the landmark Drug Quality and Security Act, bipartisan legislation to safeguard the U.S. pharmaceutical supply from counterfeit and contaminated drugs. The act creates a national system to track and authenticate prescription medications as they progress from the manufacturer to the patient. It also addresses the risks posed by drugs made by large-scale compounding pharmacies. More